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ABSTRACT 
Early onset diseases such as childhood malignancies and neurodevelopmental disorders 
have been intricate to study. For many years, research has relied and dependent upon 
different animal systems. Despite the usefulness of these systems, which have allowed the 
understanding of the biology behind these processes, the differences between species are 
still an undoubted fact. The emergence of induced pluripotent stem (iPS) cell technology 
has indeed opened new venues for many fields including disease modeling, personalized 
cell therapy, and drug screening. iPS cells have the potential to virtually differentiate into 
any cell type, hence becoming an unlimited source of disease-relevant cell types. Here, we 
present examples demonstrating the potential of disease modeling using patient-derived 
iPS cells. Neuroblastoma (NB) and Medulloblastoma (MB) are both cancers linked to 
dysregulations in pathways important during human development. Whereas NB develops 
during the peripheral nervous system (PNS) development, MB initiates during central 
nervous system (CNS) development. We have taken advantage of the early developmental 
signature of iPS cells to model cancer. We used non-cancerous cells from patients carrying 
germline mutations in cancer predisposing genes, ALK and PTCH1, and developed in vivo 
models that offer a unique understanding of cancer initiation and progression. NB patients 
carrying an ALK germline mutation were used to generate iPS cells (Paper I) and 
subsequent differentiation to Neural Crest Cells (NCC) was performed (Paper II, III). For 
this, a NCC generation protocol was optimized using intermediate levels of BMP (Paper II). 
Next, labelled NCC from patients and controls were orthotopically transplantated into the 
adrenal gland of immunodeficient mice (Paper III). Mice were followed in vivo using IVIS 
system, and we detected increased luciferase signal after more than 8 weeks but no signal 
was observed in mice injected with control NCC. After a year, adrenal glands from mice 
were harvested and one case of ganglioneuroblastoma was diagnosed, suggesting a low 
penetrance and mild phenotype of ALK contribution in NB initiation. Using a similar 
workflow, we generated Neuroepithelial stem (NES) cells from iPS cells derived from Gorlin 
syndrome patients. Gorlin patients carry germline mutations in PTCH1.  Mutations in PTCH1 
constitutively activate the Sonic Hedgehog (SHH) signalling pathway. In vivo 
transplantation of patient cells into the cerebellum of immunocompromised mice showed 
faithful resemblance of human SHH MB. By establishing NES cell cultures derived from MB 
tumors in the mice cerebellum, we could show the potential use of this model for identifying 
new targets for cancer treatment (Paper IV).  
Moreover, we exploited 2D and 3D human in vitro systems derived from iPS cells to study 
the role of p53 during early brain development. We show that p53 has an important function 
in maintaining the appropriate structure of human brain organoids. Moreover, we 
demonstrate that p53 maintains genomic instability and primes neural differentiation in 
human NES cells. Thus, revealing the role of p53 in a human in vitro context of brain 
development (Paper V). 
In summary our work presents the big potential of iPS cell technology in the field of 
modeling disease. 
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POPULAR SCIENCE SUMMARY 
Around the globe cancer is a devastating disease. Since many people think of cancer as an 
age-related disease, it is often forgotten that children can also suffer from it. Problems 
occurring during the early development of a child are most often the reason for the onset of 
cancer. Therefore, researchers try to understand what happens during that time. For ethical 
reasons, studying humans while they develop is restricted and limited. Therefore, 
researchers rely on studies that are performed in other species such as mice. Investigating 
diseases in species other than human comes with some disadvantages. For example it 
remains difficult to foresee possible side effects of a certain treatment or drug. Currently, the 
treatments that are used in children have a big impact leaving them with hormone problems 
and cognitive defects, implicating that new, better therapies are required. In 2012, a 
technique was developed that allowed researches studying human development in a dish. 
Because this technique was groundbreaking and offers new ways of conducting science it 
was awarded a Nobel Prize. From a small skin biopsy, fully mature cells could be reversed 
to an undifferentiated state by simply introducing four external factors. The resulting cells are 
named induced pluripotent stem (iPS) cells and they are equivalent to those that are present 
after fertilization. This means that these cells have now the potential to give rise to all the cells 
of the body. The technique was named cellular reprogramming. This opened a new era with 
a lot of potential for studying complicated diseases such as childhood malignancies that 
hopefully leave us with better treating options. 
In paper I, II, III and IV of this thesis we reprogrammed mature cells, like skin cells, into an 
immature state in a dish. The obtained iPS cells have been derived from patients suffering 
either from Neuroblastoma (NB) or Medulloblastoma (MB), and carried mutations that are 
inherited through generations and that predispose to these cancers. NB and MB are two 
distinct cancers emerging in different locations of children. The first one is located close to 
the kidneys, in the adrenal gland, and sometimes spreads into ganglia and nerves of the 
peripheral nervous system, whereas MB is located in the cerebellum within the brain. iPS 
cells from these patients have been directed to a more mature state in the dish, hence 
creating a more differentiated state of cells – or progenitors - that are thought to be the source 
of the disease in each case. In order to understand how the cancer occurs, we injected these 
cells into the body compartment of the mice in which these tumors usually form. Therefore, 
progenitor cells from NB patients were injected into the adrenal gland and cells derived from 
MB patients into the cerebellum. After this, we observed and followed the injected cells to 
study if they could form tumors mimicking the human disease. This approach allows us to 
study more in depth what happens during cancer initiation. Moreover, it provides tools to 
investigate potential new targets that could be useful for future treatments. 
iPS cells have been extensively used since their first appearance, and researchers have 
developed sophisticated tools to understand different diseases and general/their 
development. We used iPS cells from healthy individuals to derive three dimensional “mini 
brains” in the dish, to understand how a very important gene in tumor development has an 
effect during human brain development (Paper V). 
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1 INTRODUCTION 
1.1 CANCER 
The terminology of Cancer originates from ancient times, back to olden Greece more than 
thousands of years ago. Hippocrates (460 – 370 BC), a Greek physician, has often been 
referred to as the father of medicine. He named tumors or ulcers, carcinos, the Greek word 
for crab. It is thought that the name was probably adopted because of his empirical 
visualizations of tumor shapes and their adhesion to surrounding tissues within the body. 
Later on, carcinos was translated to Latin therefore, we refer to it as Cancer today. 
Cancer is an incredibly complex and heterogeneous disease that emerges and develops 
from normal tissues and is undoubtedly one of the leading causes of death worldwide 1. By 
the end of 2018, 9.6 million cancer related deaths were estimated 
(https://www.who.int/cancer/). Cancer incidence is increasing globally with obvious potential 
implications in the health care system. Tumors can arise from many different specialized cells 
that originate from all three germ layers of the vertebrate embryo indicating the huge variety 
and spectrum of this disease. 
1.1.1 HALLMARKS OF CANCER 
The paths that a normal cell can undertake to become malignant are multiple and intricate. 
Normal cells are tightly regulated, and especially their proliferation is securely controlled. For 
the past centuries, researchers put a lot of effort into understanding the mechanisms 
governing tumorigenesis, to find new ways to target them and improve patient survival. 
Postulating that cancer is a multi-step disease and that normal cells undergo several 
transformation events to become malignant, Hanahan and Weinberg defined six different 
biological characteristics - or hallmarks - that can initiate cancer development in normal 
tissues 2. Cancer cells have the potential to sustain proliferative signaling (1), evade growth 
suppressors (2), resist cell death (3), enable replicative immortality (4), induce angiogenesis 
(5), and activate programs of invasion and metastasis (6). All these acquired features can 
allow the cancer cell to progress. Indeed, these characteristics can be governed by different 
mechanisms and at a different time during cancer progression. As knowledge of the cancer 
field increased, new enabling hallmarks and emerging characteristics were added to this 
picture. Ten years later, four other categories were added to the already established 
hallmarks of cancer; Genomic instability allows the cell to harbor mutations that could 
potentially lead to an advantage over normal cells. A second characteristic involves the 
reaction of the immune system to promote tumorigenesis.  And last but not least, two other 
emerging hallmarks were described; the ability of cancer cells to reprogram energy 
metabolism and to be able to evade the immune system (Figure 1) 2.  
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Figure 1. Hallmarks of cancer-Next 
generation. Modified from Hanahan and 
Weinberg 2011, Cell, with permission from 
the publisher. 
 
1.1.2 CHILDHOOD CANCER VS ADULT CANCER 
Childhood cancers are rare compared to adult cancers, however in developing countries 
cancer is still the world leading cause of death in children and adolescents between 0 and 
19 years. The most common childhood cancers include leukemias, brain tumors, 
lymphomas, neuroblastoma and sarcomas 3 (Figure 2). 
   
 
Figure 2. Incidence and mortality of childhood cancers. Incidence is shown in the left panel and 
mortality in the right panel. Reproduced from Marin Navarro et al., 2018, Cell Death Discovery with 
permission from the publisher. 
However, age and incidence are not the only difference between childhood malignancies 
and adult cancers. The cell of origin, genetic and epigenetic abnormalities and the tumor 
microenvironment usually differ between children and adult tumors 4, 5. For example, whereas 
adults mainly suffer from carcinomas, which have an epithelial origin, children’s cancer are 
mostly hematological or central nervous system (CNS) tumors. These malignancies are 
considered to have an embryonic origin and probably arise in stem or progenitor cells during 
development. Therefore, childhood cancers can be described as developmental disorders.  
The early onset of appearing abnormalities could be an explanation why childhood cancers 
develop faster and harbor fewer mutations than adult cancers 6. Despite the fact that the 5-
year cancer survival rate of childhood cancer in general is about 80%, which is significantly 
better than adults, some childhood cancers such as CNS tumors, have a low survival rate 
(Figure 2). The most common treatments for childhood malignancies are chemotherapy, 
surgery and radiation. During the last decade the improvement of treatments for childhood 
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cancers has been extensive. However, despite improved survival rates, treatments can still 
lead to permanent side effects including hormone dysregulation, growth and cognitive 
effects 7, 8. For this reason, focusing on finding new treatments to target childhood 
malignancies becomes paramount. 
1.1.3 NEUROBLASTOMA 
Neuroblastoma (NB) is a rare embryonic cancer but the most common extracranial solid 
tumor during childhood. NB accounts for around 7 % of all childhood cancers (Figure 2). In 
Sweden, every year approximately 15 to 20 cases are diagnosed whereas in the United 
States around 650 cases appear (Childhood Cancer incidents and survival in Sweden 1984-
2010). NB develops in the peripheral nervous system (PNS) and primary tumors are usually 
found in the abdomen, where they are commonly observed in the medulla of the adrenal 
glands but also in the sympathetic ganglia, thus they can also be detected in the neck, chest 
and pelvic regions 9. 
1.1.3.1 STAGING AND CLASSIFICATION 
NB can be classified according to their predicative behavior which relates to genetic 
changes of the tumor. The most widely and currently used system is described in the 
International Neuroblastoma Staging System (INSS) 10, 11.  INSS is a post-surgery system and 
the diagnose is determined just after removal of the tumors. Therefore, the INSS classification 
has limitations for children who do not need or cannot have surgery. The system classifies 
NB in different stages; 1, 2 (A, B), 3, 4 and 4S. Stage 1 describes that the tumors are localized 
and completely removed without presence of metastasis. Subsequent stages worsen up to 
stage 4 which defines more aggressive tumors with presence of metastasis. Stage 4S has 
special characteristics that include children younger than one year with spread of cancer to 
other organs like liver, skin and bone marrow containing less than 10% of tumor cells. 
Frequently tumors of the 4S category regress spontaneously, a special attribute not seen in 
many cancers. However, due to the limitations of the INSS an alternative staging system was 
presented by the international NB risk group (INRG) in 2009. The INRG staging system 
(INRGSS)12, aimed to help researchers to compare their studies across the world. The 
INRGSS is based on image-defined risk factors (IDFRs) present on the imaging tests that 
allow to distinguish the difficulty of tumor removal. The stages are L1, L2, M and MS. In short, 
category L1 depicts that the tumor is well localized and contained and absent of IDFRs. 
Presence of IDFRs indicates L2 stage. The metastatic tumor grade is categorized within the 
M stage. If the tumor has metastasized strictly to skin, bone marrow or liver in children 
younger than 18 months it belongs to the MS stage, similar to the 4S stage in INSS. Together 
with other prognostic factors such as age, histology, DNA ploidy (DNA content of cancer 
cell), MYCN gene amplifications, chromosomal changes (usually deletion of 1p and 11q) and 
neurotrophin receptors status, the INRGSS provides a complete classification that separates 
patients into very low, low, intermediate and high risk groups. Based on this classification the 
nature of the cancer is identified and the best treatment strategies selected 12. Histology of 
NB is a prognostic tool used for NB classification. Usually divided in stromal component; 
Schwannian stroma rich, dominant or poor.  Schwannian stroma-poor tumors, which are the 
most aggressive ones, are sub-divided in morphologic features; undifferentiated, poorly 
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differentiated and differentiating subtypes. Calcification, and mitotic rates are also taken in 
consideration in stroma-poor tumors 13.   
1.1.3.2 THE ORIGIN OF NEUROBLASTOMA 
Elucidating the origin of NB is crucial to understand tumorigenesis. Because of its early onset 
and location of the tumors, NB it is thought to originate from PNS precursor cells 14. However, 
for obvious reasons studying the initiation of NB is difficult in humans. The majority of NB 
tumors arise anywhere along the sympathetic chain but most frequently in the adrenal 
medulla and paraspinal ganglia 15. The cells who contribute to the sympathetic nervous 
system during development are the neural crest cells, therefore thought to be involved in the 
origin of NB 16.  
1.1.3.3 THE NEURAL CREST CELLS 
The neural crest cells (NCC) were first discovered by the embryologist Wilhelm His in 1868. 
He described a cell population that emerges between the dorsal ectoderm and the neural 
tube border and is uniquely present during vertebrate embryogenesis 17. This incredible 
multipotent and transient cell population resides in the elevating neural folds in the dorsal 
neural tube until its closure during development (Figure 11 and 12 / Section 1.2.4.2). 
Subsequently, they undergo an epithelial-to-mesenchymal transition (EMT), migrating out 
from the neuroepithelium to different distant places along the embryo. Their multipotent 
capacity is defined by their potential of giving rise to a wide range of tissue types including 
craniofacial skeleton, pigmented cells, neurons, as well as glia among other cell types. NCC 
can originate from different parts of the embryo neuroaxis, which is segmented and gives 
rise to different NCC derivatives; cranial, cardiac, vagal, and trunk. Cranial NCC are a good 
example of the multipotency of NCC. They give rise to the majority of the mesenchymal 
derivatives such as bone and cartilage of the head and face but also pigmented cells, smooth 
muscle cells, nerves, glia, and connective tissue. Cardiac NCC contribute to heart 
development by forming the aorticopulmonary septum of the heart. Vagal NCC are 
responsible for the enteric nervous system of the gut and finally, the trunk NCC will 
differentiate into neurons and glia of the PNS, secretory cells, and pigmented cells 18.  
Most of the studies conducted to understand NCC development and migration have been 
carried out in chicken embryos. NCC develop upon different signaling pathways in the 
dorsal/ventral axis of the embryo including BMP and SHH signaling pathways present in the 
developing embryo 19. These studies demonstrated that during migration of the avian neural 
crest cells, signals from the dorsal aorta, such as BMP could determine the fate of NCC into 
the specific sympathoadrenal linages including the chromaffin cells or sympathetic neurons 
20, 21, 22, 23.  
1.1.3.4 GENETIC PREDISPOSITION TO NEUROBLASTOMA 
Familial NB is rare and accounts for less than 2% of all NB 24. Some mutations related to 
signaling pathways that are known to be important during development are linked to familial 
developmental syndromes and NB 25, 26. For example, PHOX2B is a homeodomain-containing 
protein which is expressed throughout the developing sympathetic, parasympathetic and 
 14 
enteric ganglia 27. The importance of PHOX2B is underlined by loss of function mutations that 
lead to congenital central hypoventilation syndrome (CCHS) and/or Hirschsprung disease. 
These are neurocristopathies that are also found in NB patients. Moreover, PHOX2B was 
identified as a predisposition risk factor for NB 28, 29, however, mutations in this gene have only 
been found in a small subset of hereditary NB and mostly associated with neural crest 
derived disorders. Besides PHOX2B, other familial mutations have been found of which ALK 
mutations are more common. Around 75% of all NB familial cancers present a gain-of-
function of ALK which makes ALK the main predisposing gene for familial NB 30. 
1.1.3.5 ALK, DEVELOPMENT AND NEUROBLASTOMA 
Receptor Tyrosine Kinases (RTK) are a large family of surface receptors that control multiple 
cellular processes which are active during development 31 and also tumorigenesis 32. 
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor 33 (Figure 3) that is 
expressed throughout the developing nervous system 34. However, the physiological role in 
human is still not entirely understood although ALK fusion proteins, overexpression, and 
activating mutations are involved in carcinogenesis of different types 35.  Addressing the 
incomplete understanding of ALK, studies in ALK knock out (KO) mice, have described 
effects in neurogenesis and in hormonal regulation 36, 37. ALK was first discovered as a 
chromosomal translocation occurring between 2;5 in anaplastic large cell non-Hodgkin’s 
lymphoma (ALCL). This translocation results in a fusion protein which is constitutively active 
38.  Mainly, downstream ALK signaling pathways have been characterized mostly from fusion 
proteins occurring in cancer. In general, ALK as a RTK is responsible for activating different 
signaling pathways such as PI3K-AKT, JAK-STAT and MAPK pathways that lead to cell 
growth, survival or differentiation depending on the cellular context 35, 39. 
 
Figure 3. ALK structure and domains. From Hallberg and Palmer, 2013, with permission from the 
publisher. Cancer Nature Reviews. 
1.1.3.6 ALK MUTATIONS  
Gain-of-function mutations in ALK have been found in sporadic 40, 41 and familial NB 42, 43 but 
also in inflammatory myofibroblastic tumors and non-small-cell lung cancer (NSCLC). 
Mutations in the kinase domain of ALK occur in around 8% of all NB (Figure 4) 44. Two hot 
spot mutations are frequently observed in NB; F1174 and R1275, the latter being the most 
frequent (85%) in NB patients. ALK R1275 mutation, is a single-nucleotide substitution within 
the activation loop of the kinase domain that leads to changes in the amino acid residues 
(Figure 4). The substitution of arginine to glutamine or leucine results in autophosphorylation 
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and autoactivation of the receptor 41.  Whereas R1275 mutations can be introduced both in 
germline and somatically 42, F1174 mutations has solely been found in sporadic tumors 43. 
Importantly, cohort studies showed that ALK mutations are associated with poorer survival in 
intermediate and high risk cases 44. Moreover, genome sequencing analysis revealed that 
relapsed NB cases have an increased frequency of ALK mutations 45 . Of note, F1174 
mutations display a higher tumorigenic potential than other ALK mutations 46, 47 but both 
F1174 or R1275 mutations contribute to and cooperate with MYCN during tumor formation 47, 
48. 
 
 
 
 
 
 
 
Figure 4. ALK somatic and germline 
mutations. Modified from Mossé et al, 2008, 
Nature, with permission of the publisher. 
 
1.1.3.7 PRECLINICAL MODELS 
Multiple NB models have been developed and established in order to gain more 
understanding of NB initiation and progression. Preclinical models are essential to develop 
new therapeutic strategies useful in clinical trials. For example, animal models including 
transgenic mouse models and xenografts have been fundamental for basic research in solid 
pediatric tumors 49. 
MYCN was identified more than 40 years ago and MYCN amplifications were found to 
correlate with poor prognosis in NB patients. Today, MYCN amplifications are still used to 
identify high risk cases 50. Therefore, a lot of focus has gone into understanding MYCN 
contribution in NB development. The most widely used tools are the TH-MYCN transgenic 
mouse model where MYCN is driven by a rat tyrosine hydroxylase gene (TH)  51, and the 
MYCN Cre-conditional mouse model that conditionally expresses MYCN in dopamine beta 
hydroxylase positive cells, like NCC 52. However, despite they have histological and 
pathological resemblance to human NB, the mouse models have limitations 53. For example, 
NB penetrance varies depending on the background of the mouse strain, as well as 
frequency of bone marrow metastasis which is often seen in human NB but low in mice. As 
an alternative, xenografts into immunocompromised mice using human NB cell lines can be 
used. One disadvantage of this model is the location of the injected cells (ordinarily 
subcutaneous injections) which could potentially affect tumor-host interactions. Therefore, 
orthotropic xenografts, which are injected into the tumor specific site of origin, have been 
used. However, NB cell lines used for xenograft are often cultured in vitro for many years 
leading to inclusion of more unknown variables. To overcome this, other methods such as 
patient derived xenografts (PDX) models have been established 54. In this case, human tumor 
material is directly transplanted into mice. PDX models are thought to be more predictive for 
clinical relevance than cell line based xenografts.  
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1.1.4 MEDULLOBLASTOMA 
Brain tumors and other CNS malignancies are the most common cause of death in children 
(0-15 years old) 55 (Figure 2). Medulloblastoma (MB) is a malignant embryonic tumor arising 
in the cerebellum and one of the most frequent cancers among children 56. The prognosis of 
MB has improved during the past decades. Resection of the tumor, chemotherapy, and 
whole brain and spinal cord radiation are first-front used therapies 57. However, patients 
suffering from relapse need new therapeutical approaches. Moreover, current treatments 
might leave MB survivors with permanent deficits as neurocognitive defects and physical 
disabilities 58. 
1.1.4.1 CLASSIFICATION OF MEDULLOBLASTOMA 
MB can be histologically and molecularly classified. Histologically MB is divided in the 
classic, nodular desmoplastic, large-cell anaplastic (LCA), and MB with extensive nodularity 
(MBEN) subtypes 59. The classic histology subtype is characterized by poorly differentiated, 
small and round-tumor cells whereas nodular desmoplastic tumors show nodular areas, 
known as pale islands, due to their white appearance. Nodular regions are usually 
surrounded by connective tissue. Additionally, the presence of reticulin rich components and 
neuronal markers can be observed. Patients with nodular desmoplastic tumors, that are often 
found in infants (less than 4 years old) and adults (more than 16 years old), generally have a 
better prognosis than patients with a classic subtype. The LCA subtype displays cells with 
enlarged nuclei, prominent nucleoli, and different amounts of cytoplasm. Moreover, tumors 
are characterized by presence of proliferation and apoptosis. LCA results in the poorest 
outcome and is classified as high risk MB. MBEN shows nodular regions with no presence 
of reticulin between the nodules. It is mostly prominent in infants and has a better prognosis 
than the rest of subtypes 60, 61 62.  
The era of transcriptomics has helped to develop new research tools to study tumor 
heterogeneity in more in depth. In addition to histological MB subtypes, gene signature 
profiling identified 4 additional subgroups of MB: Wingless (WNT), Sonic Hedgehog (SHH), 
Group 3 and Group 4 (Figure 5) 63 64. WNT and SHH groups are named due to the respective 
dysregulation in major signaling pathways and only exhibit minimal overlap based on 
methylation profile studies and transcriptomic analysis 65. Group 3 and 4 are more similar to 
each other and therefore an additional substructure its needed to clarify their differences. 
Recently, this classification has been revised and different sub-categories have been 
proposed based on distinct somatic copy-number aberrations, differentially activated 
pathways and variable clinical outcomes (Figure 5) 66.  
WNT Subgroup: WNT MB consists of tumors with abnormalities in Wnt/B-catenin signaling 
67. Almost 90% of the tumors in this subgroup present somatic mutations of the CTNNB1 gene 
which encodes the β-catenin protein. Mutations of CTNNB result in a constitutive activation 
of the WNT pathway leading to increased proliferation  68. In addition, the WNT subgroup 
harbors germline mutations in APC, a Wnt inhibitor 69 that is often associated with Turcot 
Syndrome. However, the 5-year survival rate of patients within the WNT subgroup is 
surprisingly good (Figure 5) 70 66. A recent study conducted analysis of gene expression and 
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methylation signatures of WNT MB patients. Cavalli and colleagues identified two different 
subcategories within the WNT type. The WNTα subcategory that is comprised of children 
with monosomy in chromosome 6 and WNTβ, that involves older patients with diploidy in 
chromosome 6 (Figure 5) 66. 
SHH Subgroup: Similarly to WNT group, SHH MB are named after the activation of SHH 
signaling pathway in the etiology of this group. The incidence in SHH group is higher in both 
infants and adults with intermediate risk. The histological subtype is usually limited to 
nodular/desmoplastic subtypes which makes it easier to identify tumors in the SHH subgroup 
64. The SHH subgroup contains germline mutations associated to different syndromes such 
as Nevoid basal cell carcinomas syndrome (NBCCS) and Li-fraumeni syndrome. NBCCS, 
also named Gorlin syndrome, patients can harbor PTCH1 mutations (Figure 6), therefore 
mutations affecting the SHH receptor which are often be associated with NBCCS and MB. 
PTCH1 mutations are found in 10% of all MB 71. Equally, germline mutations in SUFU have 
been linked to MB and NBCCS and are sporadically found in MB 72 73. Li-fraumeni syndrome 
patients who carry p53 germline mutations are predisposed to develop MB. Other SHH 
signaling pathway components including Smoothened (SMO), GLI1 and GLI2 have been 
found sporadically mutated in MB 64. The most recent classification distinguishes four SHH 
subgroups based on a cohort of 223 SHH MB patients; SHHα tumors affect children and 
have the worst prognosis. The SHHα subgroup is enriched with MYCN and GLI2 
amplifications and characterized by TP53 mutations all of which indicate a high risk of MB. 
Infant SHH MB is classified in two subtypes; SHHβ and SHHγ. The SHHβ subtype is generally 
considered to have a higher metastatic potential than the SHHγ subtype. SHHβ harbors more 
PTEN deletions whereas the SHHγ subtype does not show metastases, less genomic 
instability, and fewer amplifications. Subtype SHHδ includes adults and has a better 
prognosis. It is mainly defined by enriched TERT promoter mutations 66. 
Group 3: Group 3 MB have the worst prognosis of all subgroups. It is characterized by 
classic and LCA histology and often increased metastases. MYC overexpression and 
amplifications account for almost 20% of the tumors graded as group 3 MB. Additionally, 
OTX2 amplifications 63, chromosomal rearrangements that include isochromosome 17q 
(i17q), gain of 1q and loss of chromosomes 11 and 10q are typical alterations in group 3 MB 
74. Cavalli et al., identified 3 different subtypes of group 3 MB; subtypes 3α and 3β have a 
better prognosis compared to 3γ and exhibit a similar metastatic frequency. Subtype 3γ has 
the worst prognosis independently of MYC amplifications, therefore expanding high-risk MB 
beyond the MYC status of a patient (Figure 5) 12.  
Group 4: Group 4 is the most prevalent type accounting for 40% of all MBs. As well as group 
3 the tumors are characterized by a classic histology and rearrangements of isochromosome 
17q. Similarly, three different subtypes within group 4 have been identified; Subtype 4α often 
shows MYC and CDK6 amplifications. Duplications in SNCAIP are representative of subtype 
4β whereas subtype 4γ also includes CDK6 amplifications 66.  
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Figure 5. Molecular subtypes of MB. Reprinted from Cavalli et al, Cancer Cell, 2017, with permission 
from publisher. 
1.1.4.2 CEREBERAL DEVELOPMENT, SHH and MB 
As many other developmental diseases in humans, identifying the cell of origin of MB has 
been challenging and is still a matter of debate. However, there are evidences that the origin 
of MB is related to abnormalities during cerebral development. The development of the 
cerebellum is an intrinsic process beginning in early embryonic stages 75. As we know today, 
the CNS originates from the emerging epithelium of the neural tube early during development. 
During early development, the neural tube transforms drastically generating the three brain 
regions; the forebrain (Prosencephalon), the midbrain (Mesencephalon) and the hindbrain 
(Rhombencephalon). Hindbrain specification will give rise to the rhombic lip that plays an 
important role in the cerebellar neural system 76. The cerebellum consists of a cortical 
structure, subcortical nuclei and a cerebellar nucleus which projects neurons to their targets 
77. The cerebellar cortex has a simple laminar structure which contains different types of 
neurons, the granule cells, the Purkinje cells, and a diverse range of interneurons which 
coordinate the correct connectivity of the cerebellum. Cerebellar neurons are generated from 
two regions; the external granule layer (EGL) and the ventricular zone (VZ). Research in the 
past decades has shown that granule cells are produced by granule cell progenitors (GCP) 
occurring in the EGL which was initially formed from the rhombic lip.  
The SHH signaling pathway is known to control proliferation of the EGL progenitors 78. 
Secreted SHH binds to PTCH, which is highly expressed in EGL precursor cells, thereby 
ceasing PTCH inhibition of SMO (Figure 6). Subsequently, SMO activation leads to the 
release of GLI transcription factors from the cytosolic repressor SUFU and translocation of 
GLI into the nucleus where it drives target gene expression. GLI transcription factors drive 
the expression of genes that are important for proliferation - like MYC, MYCN and CyclinD1 - 
, angiogenesis, apoptosis, EMT, self-renewal, and for the regulation of the pathway such as 
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GLI1 and PTCH 79. The SHH subgroup of MB is well defined because of constitutive activation 
of SHH pathway due to mutations in genes regulating GLI activation (See section 1.1.4.1). 
Gorlin syndrome patients harbor germline mutations in PTCH1 or SUFU and are predisposed 
to develop MB showing the importance of the SHH signaling pathway in the development of 
MB.  
 
 
 
 
 
Figure 6. Schematic of SHH signaling pathway.  (Top) 
Inactive pathway occurs without the presence of SHH 
ligand. Therefore, PTCH1 inhibits SMO resulting in GL1 
being sequestered by SUFU. (Bottom) SHH binds to 
PTCH1 realizing SMO that leads to accumulation of 
GLI1. GLI1 activates several target genes linked to 
proliferation, self-renewal and suppression of 
apoptosis. 
 
1.1.4.3 MODELS OF MB 
Pre-clinical MB models have been of importance for understanding mechanisms behind MB. 
Advantages of established MB cell lines are their easy usage and possible continued culture. 
However, this can have potential implications due to selection bias or genetic drift of the cell 
lines 80. Recently, an attempt to classify the current established MB cell lines into MB 
subgroups has been made. Of 44 available cell lines, less than half have been classified. 
The most common classified cell lines are MYC amplification bearing cell lines of group 3 
MB. Currently, there are four SHH-MB established cell lines DAOY 81 UW228, UW426 and 
ONS-76 82. Half of them harbor p53 mutations (DAOY and UW-228) 83. Alternatively, tumor 
patient-derived tumor cells can be cultured and used in mice for xenografts experiments. 
Moreover, mouse models have been established with the purpose of understanding MB 
progression and the vast majority mimic the SHH subgroup 64, 84. Mice engineered with Ptch1 
mutations, knocking out Gli1, or overexpressing SMO all demonstrated a contribution to the 
development of SHH MB 85, 86, 87. Equally, expression of MYC in combination with p53 loss led 
to aggressive or high risk MB 88. Mice bearing CTNNB1 mutations mimicked WNT MB. 
However, metastasis usually is the main cause of death in children suffering from MB, which 
most of mouse models do not faithfully recapitulate, suggesting other models are needed. 
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1.2 WHY USE INDUCED PLURIPOTENT STEM CELLS FOR DISEASE 
MODELING? 
This section will discuss basic stem cell biology concepts in order to understand the use of 
induced pluripotent stem (iPS) cells for disease modeling. 
1.2.1 STEM CELLS 
Embryogenesis 
Human development begins when an oocyte gets fertilized by a sperm cell and fusion of 
genetic materials occurs. The resulting cell, called the zygote, is capable of generating an 
entire organism by rapid division of the zygote into identical cells, a process called cleavage. 
The derived structure of 16 identical cells is called Morula. After compactation and 
differentiation of the cells, the blastocyst is created. The inner cell mass (ICM) forms within 
the blastocyst whereas the trophoblasts are the cells forming the outer layer.  The blastocyst 
establishes prior to uterus implantation. The ICM is the only pluripotent lineage in the cavity 
and develops the embryonic and extra-embryonic tissues of the organism. The trophoblast 
is responsible to provide nutrients to the embryo giving rise to the placenta (Figure 7). During 
the second week, the ICM will form the epiblast and the hypoblast, forming two different 
cavities; the primitive yolk sac and the amniotic cavity 89.  Gastrulation (week 3) is the process 
in which the gastrula is rearranged and results in the formation of the three germ layers. The 
three germ layers form all the tissues and organs of the body. The three germ layers are, the 
ectoderm, the mesoderm and the endoderm. (1) The ectoderm originates the epidermis, the 
CNS, and the peripheral nervous system such as ganglia and nerves. (2) The mesoderm 
forms the dermis of the skin, muscle, connective tissue, bone, kidneys, ureters, the lymph, 
and the spleen. (3) The endoderm generates organs such as stomach, intestine, colon, liver, 
pancreas, bladder, trachea, esophagus, and the lungs. In section 1.2.4.1 I will focus briefly 
on the formation of the neural plate from the ectoderm, which creates the CNS.  (4) Neural 
crest cells (NCC) are sometimes referred to as the “fourth germ layer”. NCC emerge from 
the dorsal part of the neural tube, however, the non-neural ectoderm and mesoderm are also 
required for their formation 90. NCC will be as well discussed in more detail. 
Figure 7. Scheme of Blastocyst formation from a Zygote. To the left, the oocyte is fertilized by a sperm 
cell. Division of the zygote into identical cells occurs, Morula (middle). To the right, the blastocyst, in 
yellow the trophoblast and in gray the ICM are shown.  
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What is a stem cell? 
A cell with the capability of replicating itself (Self-renewal) and the ability to give rise to more 
specialized cell types (Differentiation) is defined as a stem cell (SC). SCs are found in multi-
cellular organisms where they exhibit their characteristics, during development or being 
resident within various tissues providing a new source for more differentiated cells. SCs are 
classified based on their differentiation potential. (1) Totipotent: SCs that can generate all 
three germ layers and the extra-embryonic tissue called the trophectoderm which gives rise 
to the placenta. During development the zygote, after fertilization, is considered totipotent 
(Figure 7). (2) Pluripotent: SCs from the ICM of a pre-implantation blastocyst (Embryonic 
stem cells) or reprogrammed by defined factors, as described in section 1.2.3 (iPS cells) 
(Figure 7). These SCs are able to generate the three germ layers and germ cells but not extra-
embryonic tissue. (3) Multipotent: Multipotent SCs demonstrate even more restricted 
potential and are only able to differentiate into specialized cell types. For example, organs 
that are exposed to constant turnover like the hair follicle, skin epidermis, and the intestinal 
crypt contain multipotent tissue resident SCs maintaining the respective organ.  
1.2.2 EMBRYONIC STEM CELLS AND IPS CELLS 
Embryonic Stem Cells 
Embryonic stem (ES) cells are pluripotent stem cells derived from the ICM of the embryo 
(Figure 7). About 30 years ago, in 1981, the first ES cells were isolated from a mouse 
blastocyst 91 and they could be cultured on mouse embryonic fibroblasts (MEFs) 92, 93. Almost 
10 years later, it was possible to isolate ICM cells from the human blastocyst 94 and passage 
them long term in cell culture systems 95. The maintenance of cells that are able to differentiate 
into a distinct range of specialized cell types in vitro bears huge therapeutic possibilities 96. 
However, for that to be possible, a lot of focus has been into developing better cell culture 
conditions. Hallmarks of successful ES cell culture are; (i) indefinite self-renewal, (ii) 
maintaining a normal euploid karyotype over extended cultures, (iii) expression of 
pluripotency markers (iiii) and to sustain differentiation potential into derivatives of all three 
germ layers 96, 97. Different surface markers are used to characterize ES cells. Examples are 
SSEA-4, TRA 1-60, and TRA 1-81 that were originally identified in embryonal carcinoma cells 
and human pre-implantation embryos 98. Similarly, a number of transcription factors that play 
important roles in maintaining self-renewal, are currently used to characterize isolated ES 
cells from blastocysts. For example, the transcription factor Oct3/4 99 100, Sox2 101 and Nanog 
102. Isolation of ES cells from human embryos has tremendous potential in clinical 
applications, however ethical concerns have to be taken into account. 
Induced Pluripotent Stem Cells 
Pioneering work by John Gurdon back in the 1960s demonstrated the cloning potential by 
transferring a nucleus from a somatic cell of a tadpole into an enucleated egg 103. It was not 
until 2006, that Shinya Yamanaka and colleagues made the discovery that four factors, Oct4, 
Sox2, Klf4 and c-Myc (OSKM), when ectopically introduced, were capable of reprogramming 
a somatic mouse cell into a state of pluripotency 104.  One year later they were able to confirm 
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this for human cells 105. Yamanaka’s research demonstrated that fully differentiated and 
matured cells retain the potential which resembles the embryonic stage. This groundbreaking 
discovery, together with Gurdon’s work, was awarded a Nobel Prize in 2012. Their research 
demonstrates an indefinite potential for disease modeling and regenerative medicine. Similar 
to ES cells, iPS cells express markers of an undifferentiated state and possess the capacity 
for self-renewal and differentiation to any cell of all three germ layers. Human ES cells are 
bound to multiple ethical regulations due to the destruction of the embryos whereas iPS cells 
offer a clear ethical advantage, representing an unlimited source of any cell type of interest 
106.  
1.2.3 REPROGRAMMING, CULTURE CONDITIONS AND CHARACTERIZATION 
OF IPS CELLS 
Cellular reprogramming occurs when a somatic cell resets back to the pluripotent stem cell 
state. During recent years, various methodologies have been developed to achieve this.  
Here, we focus on reprogramming via ectopic expression of defined transcription factors, 
therefore even though somatic cell nuclear transfer, cell fusion and direct reprogramming are 
also approaches that are or have been used, they will not be the focus in this thesis but is 
reviewed in 107.  It is important to note that reprogramming is achieved differently depending 
on the cell source, usually attributed to differences in endogenous levels of reprogramming 
factors (Figure 8, left), as well as the delivery method of choice (Figure 8, right) 108. 
Summary of reprogramming methods 
Ectopic expression of OSKM in somatic cells promotes their transition to a pluripotent state. 
Takahashi and Yamanaka used retroviral vectors in order to reprogram mouse and human 
fibroblasts 104, 105. However, nowadays different methods are used to generate iPS cells. 
These techniques include integrative and non-integrative methods that allow for different 
efficiency and safety of reprogramming. Integrative methods utilizing retro- and lentiviral 
constructs involve integration of the genetic material into the host genome. Retroviruses were 
used in the original studies conducted by Yamanaka and offer an efficient and easy form of 
delivery. In the same way, lentivirus integrates into the host genome. However, their capability 
of integration in the host genome comes with risk of mutagenesis 109. Other risks of the two 
viral methods include the reactivation of transgenes with the implication of off-target effects. 
The transfection with plasmid or linear DNA and transposons, presents an alternative to viral 
vectors, although quite inefficient. On the other hand, non-integrative methods overcome 
the safety risks mentioned above, thus being a preferable choice. Some of these techniques 
are DNA based methods such as adeno- or RNA based viruses as the often used Sendai 
virus (SeV). However, adenoviruses are labor intensive to produce and require multiple 
infections. In contrast, SeV, a negative-strand single stranded RNA virus, is an efficient 
expression method that expresses the transgene without host genome integration. Of note, 
the viral genome remains in the host cell for a period of time due to which extended 
passaging is required 110. Episomal vectors are extrachromosomal DNA that replicates 
independently from the host DNA. They are compared to viral vectors a low-cost solution. 
Their disadvantages are the relative inefficiency, and the requirement of serial transfections. 
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Last but not least, mRNAs transcribing the four factors OSKM and Lin28 are able to 
reprogram a somatic cell via transfection methods. The reprogramming mRNA is modified 
that reduces the immunogenicity of this technique 111. All in all, the reprogramming method is 
of choice and mainly depends on the application and purpose of the desired cells (Figure 8, 
Right panel). 
 
Figure 8. Reprogramming Strategies. By González et al, 2011, with permission of the publisher, 
Nature. 
Nuclear reprogramming by defined transcription factors (OSKM) 
Whereas, Oct4 112, Sox2, and Nanog are key regulators of embryonic development and 
expressed in the ICM of the blastocyst, Nanog is not essential for the reprogramming process 
104, 113. Klf4 has key roles in development, proliferation and differentiation and is expressed in 
ES cells. C-Myc is a proto-oncogene and among other functions linked to proliferation, 
differentiation and apoptosis. Moreover, it is associated with acetyltransferase complexes 
allowing the chromatin to relax. Thereby, it facilitates Oct4 and Sox2 binding to their 
respective loci and drive the expression of target genes which induces reprogramming. 
Oct4, Sox2, and Nanog cooperate in order to maintain expression in an auto-regulatory 
manner. High expression of c-Myc can lead to increased levels of p53 which might potentially 
promote apoptosis during reprogramming. However, Klf4 has been shown to block p53 thus 
subsequently allowing reprogramming 114, 115. Collectively, downregulation of p53 has been 
shown to increase reprogramming efficiency 116. 
The process of reprogramming consists of two phases, the stochastic phase (phase 1), 
which is the initial phase and the hierarchical phase (phase 2). During phase 1, lineage-
specific genes are downregulated, probably due to direct effects of OSKM and subsequent 
upregulation of pluripotent markers. Next, remodeling of the chromatin occurs with activation 
of endogenous pluripotent genes 117. Initiation of phase 2 begins when Oct4, Sox2, and 
Nanog are able to be expressed endogenously and thereby reactivate the auto-regulatory 
loop that leads to restoration of the pluripotency network. This process includes self-
maintaining of pluripotency genes and the reactivation of telomerase. Notably, epigenetic 
changes take place during reprogramming and are important for iPS cells properties 118. 
Somatic cells contain condensed heterochromatin, compared to iPS cells which has a more 
accessible and open chromatin conformation. Moreover, activating histone marks and 
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hypomethylation of DNA for pluripotency genes are some of the processes that are involved 
in the reprogramming and maintenance of pluripotency 119.  
Culture conditions 
Optimization of cell culture conditions for iPS cells are crucial to increase safety of production, 
generate homogenous cultures of iPS cells, and for final clinical application purposes. The 
main goal during the past decade has been the development of chemically defined, and non-
animal derived components (xeno-free) to derive and grow iPS cells for regenerative 
medicine and drug discovery. This allowed for a better standardization of protocols, 
avoidance of spontaneous differentiation, and heterogeneity of expanded cells 120. Therefore, 
cell culture conditions are crucial for the maintenance of high quality iPS cells including their 
pluripotency features and differentiation potential. Briefly, in vitro iPS cell culture need (i) 
growth media, (ii) extracellular matrices and (iii) environmental factors. 
(i) As mentioned peviously, the ultimate goal for therapeutic use of iPS cells is to 
develop serum-free, xeno-free, and chemically defined media. The first medium 
used to culture pluripotent stem cells contained fetal bovine serum (FBS) and cells 
were cultured on Mouse embryonic fibroblasts (MEFs) also refered to as feeder 
cells. MEFs are responisble of secreting growth factors needed for the mantaince 
of the co-cultured iPS cells. Today, media are more standarized and better 
defined as a result of replacing most of the xenogeneic elements121, 122. Thus, 
defined medias contain protein components from human or recombinant origin 
that allows for feeder-free conditions (see (ii) for feeder-free conditions)  123. 
 
(ii) Pluripotent stem cells including ES cells and iPS cells, grown in vitro as 
monoculture are in need of supporting factors. Typically pluripotent stem cells 
used to be cultured on mitotically inactivated MEFs 93. MEFs  secrete growth 
factors that support iPS cell in culture. However, MEFs can be a source of viral 
and bacterial contamination. Of note, there is requirement of animal products 
such as FBS supplemented medium for MEF cultivation. In addition, laborious 
preparation is required for their mantainance. For these reasons, large production 
of iPS cells is not feasible in culture conditions based on MEFs. Feeder-free 
systems have been developed based on components of the extracellular matrix 
(ECM). Indeed, in absence of feeder cells, factors that promote survival and 
proliferation are still a requisite. Currently, matrixes such as Matrigel TM are utilized 
to maintain pluripotent stem cells. Matrigel is extracted from Engelbreth-Holm-
Swarm mouse tumor and contains a mixture of ECM components; fibronectin, 
collagens, and laminins in addition to various growth factors. Despite its ease of 
use, batch to batch variations and animal derived components display a 
disadvantage depending on the final application of the cells. Alternatives are 
recombinant fibronectin or vitronectin which are part of the ECM and are rich in 
arginine glycine aspartate peptide sequences, required for cell-cell adhesion  124. 
Laminins are glycoproteins present in the ECM and constitute the basement 
membrane. Furthermore, laminins are expressed in human ES cells 125. Recently, 
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human recombinant laminins have been reported to maintain long term self-
renewal of pluripotent stem cells and allow for clonal derivation and survival 126, 
127. Cell culture conditions are extremely important not solely for maintaining 
pluripotent characteristics but also to retain genomic stability 128. Importantly, it 
has been shown that cell culture conditions such as media, passaging methods, 
and supplements can induce mutations for example in p53 129, an important 
regulator of genomic stability in the cells. 
 
(iii) Enviromental cues include physical and phyisiological cues that iPS cells are 
subjected to when grown in vitro. Examples of environmental cues are passaging, 
cryopreservation, humidity, oxygen levels, and temperature. 
Characterization of pluripotency 
One requirement after generation of iPS cells is the validation of the cell potential in terms of 
pluripotency and differentiation. A diverse range of methods are used to assess pluripotency, 
most commonly morphology, expression of surface markers, and transcription factors that 
indicate an immature state and assess differentiation potential. Typical surface markers are 
SSEA-4, TRA-1-60 and TRA-1-81 which can be analyzed using simple molecular techniques 
such as immunocytochemistry or flow cytometry. The transcription factor OCT4 is expressed 
in pluripotent cell populations both in vivo and in vitro and its downregulation takes place 
during differentiation 112 99. Similarly, SOX2 is essential to maintain cell pluripotency and self -
renewal 130 whereas NANOG cooperates with SOX2 and OCT4 to maintain pluripotent 
properties 131. Gene expression profiling is essential to determine molecular signatures that 
are unique for ES and iPS cells. For example, bioinformatics tools such as the PluriTest have 
been a step forward for the characterization of pluripotent stem cell lines. This is an easy-use 
bioinformatic tool based on gene expression profiles of around 300 pluripotent stem cell 
lines132  which allows for a good indication of the cell line quality. However, the expression of 
pluripotent markers is not exclusively important to assess the full pluripotency potential of the 
reprogrammed cells. Due to the possibility of clonal selection occurring during cell culture 
techniques and high proliferation rates, in vitro iPS cells need to be routinely checked for 
genomic integrity 128. To assess differentiation potential in human pluripotent stem cells, 
teratoma formation has been widely used. To check for teratoma formation iPS cells are 
injected into immunocompromised mice and the resulting teratoma is validated for the 
presence or absence of the three germ layers. Similarly, markers for the three germ layers 
can be validated in vitro after generation of embryoid bodies (EB). Since epigenetic 
phenomena are a hallmark during reprogramming as well, studies of the epigenetic 
landscape of iPS cells can be used as a tool for characterization.  
1.2.4 DISEASE MODELING WITH IPS CELLS 
Disease modeling 
The development of iPS cells opened up new avenues for disease modeling, drug screening 
and discovery, and regenerative medicine including cell transplantation therapies. This 
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thesis focuses on disease modeling as one application for iPS cells. Most of the current 
systems used to study cancer rely on murine model organisms and in vitro systems of 
immortalized or primary cell cultures. Despite the usefulness of these models, interspecies 
differences cannot be ignored, such as differences in disease progression and drug 
response 133. In addition, prolonged culture of cancer cells can alter their characteristics 
compared to the tumor source. It has been shown that only 5 % of tumor associated genes 
were expressed in the cell lines when compared to the original tumor 134. 
iPS cell technology provides great advantages due to the ease of cell generation from any 
individual in context with its own genetic background. One of the most attractive features of 
iPS cells is their representation as an indefinite source of disease-relevant cell types. Patient-
derived iPS cells demonstrated potential to uncover mechanisms that have been unknown or 
poorly understood in humans. Moreover, iPS cells provide disease-relevant cell types useful 
for drug screenings 135. 
Modeling disease with cancer-predisposing genes 
Complex diseases with sporadic origin and late onset have been successfully modeled using 
iPS cell technology 136, 137, 138. This also applies to modeling diseases such as cancer 139. The 
first reports involved the establishment of iPS cells from a diverse range of cancer cells as 
proof of principle 140, 141, 142. Pancreatic ductal adenocarcinoma (PDAC) lacks models to 
understand early stages of the disease 143. A study showed that iPS cells derived from 
pancreatic cancer cells could recapitulate the early stages of PDAC. In addition, the model 
was used to identify novel targets for the diagnosis and treatment of PDAC 143 (Figure 9a). 
However, due to the genomic and epigenetic complexity of cancer cell lines, the 
reprogramming process of cancer cells has been challenging. Although some studies have 
shown that pluripotency can pause cancer progression and restore differentiation in vitro 144, 
others tested the effect of reprogramming in vivo. Partial reprogramming in vivo did not lead 
to teratomas but severe tissue dysplasias145. Therefore, other approaches can be used in 
order to not solely model the disease but understand the contribution of certain alterations in 
cancer development. Germline mutations are rare, however 43% of cancer predisposition 
genes with germline mutations overlap with mutations found in sporadic tumors 146. Lee and 
colleagues, reprogramed fibroblasts from Li-Fraumeni syndrome patients (LFS) that carry 
hereditary mutations in TP53.  These mutations led to the onset of site-specific cancers 
including osteosarcoma, breast cancer, and brain tumors 147. Because murine models do not 
fully recapitulate the tumor spectrum of these patients and p53 is usually linked to other 
oncogenic drivers, other models were needed to decipher the role of p53 in cancer 
development. LFS patients’ healthy fibroblasts were reprogrammed into iPS cells and 
differentiated into osteoblasts with successful recapitulation of osteosarcoma lead to the 
identification of regulatory mechanisms which bears the potential for clinical implications 147. 
Therefore, many different patients could potentially benefit using this same approach (Figure 
9b).  
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Figure 9. Approaches to model cancer using patient-derived iPS cells. Cancer cells from the patient 
can be reprogrammed to be used for establishing new models and drug screening platforms (a). 
Somatic cells carrying germline mutations in a cancer patient are used to generate iPS cells that in 
turn are used for disease modeling and drug testing in vitro and in vivo. Marin Navarro et al, 2018, Cell 
Death Discovery, printed with permission from the publisher. 
Here, the focus will be on using non-cancerous cells for reprogramming albeit carrying 
germline mutations implicated in the development of cancer. We have established models 
that allow monitoring of tumor formation from the first genetic hit. 
(i) Hereditary Neuroblastoma 
PHOX2B and ALK mutations have been found in hereditery NB 148 being perfect 
candidates to establish iPS derived models. Germline mutations in NB are rare, 
however as previously described in section 1.1.3.4 24, they are found sporadically 
and can thus be used to model NB using patient-derived iPS cells.   
 
(ii) Inherited Medulloblastoma-associated syndromes 
Germline mutations in PTCH1 are linked to Gorlin syndrome, which is a 
predisposition to basal cell carcinomas, congenital abnormalities, and MB. Other  
mutations in genes such as SUFU and APC can be associated to different 
syndromes predisposing to MB and other cancers.  Therefore, using iPS cells 
derived from patients carrying these germline mutations can be benefitial to 
understand not only MB but a broad range of other related diseases.  
1.2.5 MAKING THE RIGHT PROGENITOR FOR CANCER MODELING 
Modeling cancer using patient-derived iPS cells undoubtedly opened new insights in basic 
research and unraveled new potential clinical targets. The repertoire of cell types that can be 
derived from iPS cells is immense. However, generating the right progenitor or relevant cell 
type to best mimic disease is most important. Identifying the most relevant cell type for every 
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disease we would like to model, is as crucial as the validation of pluripotency of iPS cells in 
the first place. After identifying the cell type of interest, there are a few aspects to take in 
consideration such as; available differentiation protocols, efficiency of the protocol, 
homogeneity and quality of the resulting cell population, and maintenance and 
characterization of the cultured cells. In this thesis, we aimed to model two different childhood 
cancers, NB and MB. In order to do that, we first required to generate what is thought to be 
the cell of origin of each respective disease. Therefore, I revise two different progenitors that 
can be differentiated from iPS cells; Neural Stem Cells (NSC) and NCC, in chronological order 
during development. 
1.2.5.1 NEURAL STEM CELLS FROM IPS CELLS 
Neurulation during development 
Neurulation in vertebrates is the formation of the neural tube which gives rise to the central 
nervous system; the brain and the spinal cord. For this to happen a mesodermal structure, 
the notochord, needs to be formed and acts as the major axis in the body after the three 
germ layers are generated. The notochord will orchestrate the ectoderm to become a thick 
flat plate of cells that we commonly name the neural plate. Importantly, this plate is composed 
by a single cell layer that forms the neuroepithelium. The neural tube extends from the rostral-
caudal axis which bends in a tube shape known as the neural tube. The neural tube sits just 
underneath the ectoderm. During a process in which the neural plate borders fuse to each 
other NCC emerge and migrate out to other parts of the embryo (Figure 10).  
 
 
 
 
 
 
 
 
 
Figure 10. Neurulation process. The neural plate border (green) 
and in between, the neuroectoderm (blue). During the process of 
neurulation, the neural plate borders form neural folds which 
elevate and fuse with each other resulting in the formation of the 
neural tube. NCC will delaminate from the dorsal part of the neural 
tube. Gammil & Bronner-Faser, with permission of the publisher, 
Nature 2003. 
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Neuroepithelial stem (NES) cells and Neurogenesis 
Neuroepithelial stem (NES) cells form the neuroepithelium present in the neural plate during 
neurulation.These represents the primary neural stem cells (NSC) which can divide 
symmetrically, giving rise to two identical daughter cells (self-renewal), or asymmetrically, 
which generates an identical daughter cell plus a second more specialized cell type, in this 
case, a radial glia (RG) cell or a neuron type 149. RG which are more restricted than NES cells, 
display astroglial properties and generate most of the neurons in the brain. This differentiation 
process from NSC to neurons is called neurogenesis 150. Consequently, NSC are in charge 
of forming all neurons from CNS. 
NSC from iPS cells  
Understanding human neurogenesis and brain development is crucial to elucidate CNS 
related diseases such as neurodegenerative and neuropsychiatric disorders, and brain 
tumors. Therefore, the scientific community has put a lot of effort trying to understand NSC 
function and their differentiation. The possibility of obtaining unlimited neural stem cell 
progenitors in vitro from pluripotent stem cells has been a major advance for disease 
modeling and regenerative medicine. Neural induction has been extensively studied in 
Xenopus and chicken embryos. Mechanisms underlying neuroectoderm differentiation 
involve BMP, WNT, and FGF signaling pathways151. The first protocols addressing pluripotent 
stem cells were based on EB formation. Usually performed in the presence of serum or serum 
replacement with formation of neural rosettes, a morphology indicative of the neuroepithelium 
152, 153, 154. In 2009, Chambers et al, established an optimized protocol targeting both branches 
of the SMAD signaling pathway by using Noggin, a BMP inhibitor, and SB431542, a TGF-
β/Activin/NODAL pathway inhibitor, which block BMP and TGF-β pathways that utilize SMADs 
as transducers. This allowed for the exit of cells from the pluripotent state while blocking the 
formation of mesoderm and non-neural ectorderm achieving higher efficiency of NSC 155. In 
presence of FGF and EGF, NSC can be propagated in vitro 154, 156.  
1.2.5.2 GENERATING HUMAN NEURAL CREST CELLS  
Signaling pathways during NCC development 
The complex nature of NCC during embryogenesis has been reviewed in section 1.1.3.3. 
NCC multipotency leads to the generation of a wide spectrum of cell types that constitutes 
the body (Figure 11).  Therefore, it is not surprising that deregulation during NCC 
development implicates various human diseases but also a promising potential for clinical 
applications 157.  Most of our understanding in NCC biology has come from chicken embryos, 
zebrafish and mouse. NCC emerge at the border of the neural plate (Section below, Figure 
10 and 11) and the non-neural ectoderm that will later form the epidermis. When the neural 
plate folds (Figure 10), the neural folds from each side of the ectoderm come together and 
fuses (Figure 10). During the neural tube closure, NCC migrate out colonize the embryo and 
differentiate (Figure 11). The regulatory gene network that governs and regulates NCC 
formation and differentiation is extremely complex 158. It is currently understood that NCC 
induction occurs during early gastrulation mediated by BMP, WNT and FGF signaling 
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pathways 159.  First evidences in Xenopus showed the importance of BMP signaling pathway 
during NCC formation. The growth factor BMP4 was produced prior to neural induction 
inhibiting neural tissue formation and instead promotes the formation of the epidermis. 
Antagonists of BMP block this process in order for neural induction to occur 160. However, 
later studies showed discrepancies on how this process take place and several models have 
been proposed 161, 162. Nevertheless, it 
was established that intermediate 
levels of BMP are required but not 
sufficient for NCC induction. Indeed, 
the cooperation of other signaling 
pathways is necessary for NCC 
formation 158.  For example, members 
of the WNT family and FGF signaling 
pathways have been shown to play a 
role in NCC development163, 164.  
Figure 11. Derivatives of NCC. NCC migrate out from the dorsal neural tube after its closure. With 
permission from the publisher. Knecht & Bronner-Faser, Nature Reviews, 2002. 
NCC derived from iPS cells 
Most protocols for the generation of NCC from pluripotent stem cells rely on the 
understanding of NCC biology 158 and studies in which human pluripotent stem cells could 
be differentiated into neuroectoderm 155, 165. Lee and colleagues showed the presence of NCC 
at the neural rosettes stage by co-culturing ES cells on stromal cells. However, the use of co-
culture systems is inefficient and heterogeneous, thus not ideal for most of applications. In 
2010, the same group improved the protocol developing a feeder-free system using the 
SMAD dual inhibition strategy (also see section above, 1.2.4.1). Therefore, defined medium 
containing Noggin (BMP inhibitor) and SB431542 (TGF-β/Activin/NODAL pathway inhibitor) 
was used 165. Despite the inefficiency of the protocol, the combination of these two factors 
and culture conditions was a major breakthrough that initiated a new era of NCC generation 
protocols. In 2011, Menendez et al 166 combined WNT pathway activation by inhibiting GSK3, 
a WNT antagonist and the suppression of TGF-β/Activin/NODAL pathway. In this study, it was 
observed that BMP inhibition was not required for NCC generation 167. In 2013, Mica and 
colleagues reported that an initial pulse of BMP inhibition and TGF-β/Activin/NODAL 
pathways followed by WNT activation and withdrawal of the SMAD dual inhibition strategy 
increased efficiency of NCC generation. Collectively based on the mentioned studies, it 
becomes clear that the effect of BMP signaling during NCC generation from human 
pluripotent stem cells still remains unclear 
1.2.5.3 BRAIN ORGANOIDS 
Organoids derived from pluripotent stem cells 
Until now, the relevance of 2D systems has been discussed. However, in vitro 3D systems 
have shown to be structurally and physiologically more similar to the recapitulation of an in 
vivo situation. 3D in vitro systems display higher complexity, are functionally and structurally 
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more representative of cellular organizations 168, 169. Already, in 1965 cell dissociation and 
cellular aggregation was used to describe an organoid in developmental biology studies. 
Today, this concept has developed further and a new definition of organoids has been 
created; 3D structures that originate from stem cells and are constituted of tissue-specific 
cell types that spatially organize 170. Pluripotent stem cells have been used to generate many 
different organoids like brain, gut, kidney and retina 170. Therefore, the generation of patient-
specific organoids from iPS cells holds a promising step forward in the comprehension of 
disease modeling, drug testing, and gene therapy. 
The human brain  
The brain is the most complex of all organs of the animal kingdom. To understand brain 
development, animal models have been extensively used and thus are the basis of most of 
our knowledge about the brain. Specific features and functional studies in human brain have 
been completely limited to post-mortem observations. Thus, scientists have been in need to 
establish in vitro models close to in vivo brain development. Whereas two-dimensional cell 
culture has been vital for the study of the brain, it is clear that the recapitulation of complex 
and diverse cell structures is limited. 2D systems can be quite homogenous, with presence 
of non-solely neural tissue that is far from the in vivo situation.  
As previously described, the brain develops from the neuroepithelium, more specifically from 
a sheet of NES cells in the neural plate. During brain development, the ventricles are formed 
after the neural tube closure. Adjacent to the ventricles, the NES cell layer is present and its 
major function is to proliferate with the purpose to increase and expand the number of 
progenitors before neurogenesis commences. This proliferative zone is named the 
ventricular zone (VZ). During the division of progenitors, a process named interkinetic nuclear 
migration (INM) takes place which consists of the movement of NES cell nuclei from the basal 
to the apical side of the neuroepithelium 171. This is a typical process within the epithelium 
and it is essential for the cells to find the right position and initiate mitosis during entire 
neurogenesis. Right before neurons are born, NES cells change their biological properties 
and become RG cells 172. Recently, it has been shown that RG differ in between different 
niches. In a vertical plane, RG cells continue to divide symmetrically but additionally 
asymmetrically giving rise to either another progenitor or a neuron. In humans, the beginning 
of neurogenesis initiates during week 5 and 6 of gestation. Importantly, RG will establish 
another neurogenic niche, the subventricular zone (SVZ) that is different from the VZ because 
of a different cell orientation and marker expression profile 173. At that particular stage RG are 
named intermediate progenitors or basal progenitors that divide symmetrically giving raise 
two neurons each time 174. The expansion of the neocortex occurs according to this process 
of divisions, being generated from different progenitor and neurons that migrate basally and 
organize themselves in layers. While the deepest layers of the cortex will contain the oldest 
neurons, the newest neurons will migrate to the most outer part of the cortex. Together, the 
fully formed neocortex contains 6 neuronal layers 175. 
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Figure 12. In vivo versus in vitro human 
brain. (Top) The human brain in early and 
late development. (Bottom) 
Representation of the organoid during 
early development, similar to human and 
late development which shows structural 
and cellular differences.  
 
 
 
 
 
 
 
 
 
Brain organoids from iPS cells  
The cellular biological features of all the various cell types contributing to human brain 
development are extremely complex and heterogeneous, even though it has been simplified 
here, a more detailed overview can be revised in several reviews 175, 176. In vitro establishment 
of neural progenitors has shown to be capable of recapitulating and differentiating into a 
diverse range of specific neurons including layer specification 177. However, considering the 
complexity of an organ such as the human brain, 3D culture methods represent a great 
advantage in the field.  
Based on the notion that ES cells spontaneously differentiate into neural fate without the 
presence of inhibitors 178, Sasai improved culture of 3D methods using floating EB in serum-
free conditions (SFEB) 179. This, included reaggregation of cells and subsequent seeding on 
coated dishes. With the addition of specific signals and when plated, forebrain progenitors 
were generated (SFEBq) 180. Mariani et al, showed that modification of this protocol allowed 
for a fair recapitulation of the developing forebrain 181. Although it was clear that neural 
induction did not require help of serum or other morphogens, the efficiency of the protocols 
had to be optimized. As explained in section 1.2.4.1, germ layer specification depends on 
several signaling pathways such as TGF-β that includes SMADs as downstream effectors. 
With this, Chambers et al, engineered a combination of factors that promoted differentiation 
of neural progenitors from pluripotent stem cells overcoming the need of using EB formation 
155. A consequence of this was a blooming era for neural differentiation from pluripotent stem 
cells. From this point of view, 3D organoids, as we know them today were just an emerging 
era at that particular time. Hans Clevers demonstrated that intestinal stem cells could 
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generate tissues in 3D structures that resembled the special structure of the intestinal crypt 
and epithelium 182. The use of ECM components was a relevant difference compared to other 
protocols. ECM supported growth and spatial structure of the epithelia, which organized 
using a basal-apical orientation. In the same manner, many other epithelial organs have been 
modeled such as stomach 183, lung 184 and esophagus 185. The breakthrough that ECM, 
concretely matrigel, was supportive of epithelial structures was an important step forward for 
the development of brain organoids as well. Madeline Lancaster generated brain organoids 
through a combination technique that includes the embedding of EBs in matrigel. Importantly, 
these organoids present a different variety of cellular identities including hind-, mid- and 
forebrain cells thus referred to as whole-brain organoids 168. On a cellular level, it is incredible 
to see the resemblance of the in vivo early developing human brain with the 3D cultured 
organoids. Figure 12 represents the structural and cellular similarities of early stages of brain 
development compared to 3D brain organoids (a and b, left panel) whereas in later stages 
present a bigger difference. Figure 13 shows the transcriptomic resemblances between an 
in vivo human developing brain and a 3D brain organoid. 
 
Figure 13. Timeline of the human developing brain. Purple indicates similarity between in vivo and in 
vitro systems based on cell-biological transcriptomic data of different studies. pcw – post-conception 
weeks186. With permission of Elsevier, Kelava et al, 2016, Cell Stem Cell. 
1.3 TP53, THE GUARDIAN OF IT ALL 
p53 is a transcription factor belonging to the p53 family, which also includes the transcription 
factor members p63 and p73 187. This family is evolutionary conserved which means that its 
origin traces back over a billion years ago. Thus, all members of the family share structural 
homologies. Of note, in humans each of these genes is located on a different chromosome. 
p53 for example, is situated on 17p13.1, p63 on 3q27-29, and p73 is located on chromosome 
1p36.3. Even though they share similar structures, they do not necessarily exert the same 
functions 188  . However, in this thesis only p53 is reviewed. 
1.3.1 STRUCTURE, FUNCTION AND REGULATION 
Structure of the p53 protein 
The p53 gene encodes for a 393 amino acid protein that forms a homotetramer. The N-
terminal part of the protein contains two distinct regions; a transactivation domain (TAD) and 
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a proline-high region. The TAD region is especially important for protein-protein interactions 
for example with MDM2, a negative regulator of p53. The core of the protein constitutes the 
structure for a DNA binding domain (DBD), an immunoglobulin-like-β-sandwich that acts as 
a scaffold for DNA, followed by the oligomerization domain (OD) permitting for the 
tetramerization of the protein. Last but not least, the c-terminal domain (CTD) undergoes 
posttranslational modifications such as ubiquitination and phosphorylation that leads to 
different regulations and functionalities of this protein 189. Most of p53 research refers to the 
full length protein, however up to twelve isoforms are encoded from the same gene, with and 
without presence of the TA domain 190. 
Versatile functions of p53  
p53 is a transcription factor that is activated as a result of many cellular stresses such as 
DNA damage, oxidative stress, and oncogene activation among others. The main role of p53 
is to protect the cell by attempting DNA repair, blocking cell cycle or inducing apoptosis 191.  
One of the most well-known effectors of p53 is p21, which blocks cell cycle by interacting 
with cyclin-dependent kinase complexes, preventing phosphorylation of RB proteins and 
inactivating E2F-dependent transcription 192. Importantly, p53 regulates DNA repair and 
genomic stability. One of the mechanisms that p53 induces upon DNA repair is apoptosis by 
the activating the transcription of pro-apoptotic genes. For instance, the p53 target BAX 
inhibits the pro-survival family bcl-2 193, or the p53 upregulated modulator of apoptosis 
(PUMA) can bind directly to Bcl-2 leading to cytochrome-c release from mitochondria 194. On 
the other hand, p53 controls genomic 
stability by regulating centrosome 
duplication 195. Another function 
regulated by p53 are metabolic 
pathways such as glycolysis and 
oxidative phosphorylation 196 with 
further implications in proliferation and 
cell fate determination. Moreover, 
cellular reprograming is antagonized 
by p53. In line with this, OCT4 and KLF4 
repress p53 transcription 197. However, 
at a cellular level, p53 controls many 
distinct functions by exerting its 
transcriptional activity of many genes 
(Figure 14).  
Figure 14. Network of regulators, functions and target genes of p53. Kustenhuber and Lowe et al, 
2017, with permission of the publisher, Cell. 
1.3.1.1 TP53 DURING DEVELOPMENT 
p53 is a well-known tumor suppressor thus, playing an important part in cancer development. 
Mutations leading to inactivation of p53 are shown to be one of the most common events in 
adult human cancers. Unfortunately, p53 loss is usually associated with poor prognosis 198. 
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However, since p53 regulates such vast range of functions, mostly tumor suppressor 
functions, whether p53 is important during early brain development is still poorly understood. 
In normal cells, p53 levels are low and is not until a stress-induced signals occurs that p53 
can be released from regulators such as Mdm2. Mdm2 is an E3-ubituitin ligase that flags p53 
for proteosomal degradation 199. Mdm2 KO mice are lethal by early embryonic stage during 
implantation, and this phenotype is rescued by depletion of p53 indicating the importance of 
negative regulation of p53. An elegant study showed that p53 knocked in mutant mice 
revealed lethality at E10.5 and between E13.5-15.5 varying on the p53 levels. In this study, it 
was described that unappropriated activation of p53 led to several developmental 
abnormalities including; brain, heart and bone/cartilage defects 200. When looking into the 
mouse system, p53 is highly expressed during development, therefore it was surprising that 
the first study reporting p53 KO mice did not show developmental problems, yet quick tumor 
burden was observed 201. Later, two different groups showed that p53 KO mice exhibit 
exencephaly, a neural tube disorder, as a major developmental problem in p53 KO mice. 
Nevertheless, this phenotype was varied depending on genetic background and gender of 
the mice 202, 203. 
p53, brain development and stem cells 
At embryonic day 10.5 (E10.5), p53 mRNA is shown to be expressed ubiquitously throughout 
the whole brain 204. At the time that differentiation and specification occur, p53 expression 
becomes limited to the cortical plate 205. Transgenic mice expressing lacZ under a p53 
promoter confirmed high transactivation of p53 during E10.5 206, specifically between the 
midbrain region of the brain and the cerebellum. In newborn mice, p53 is localized in cerebral 
cortex regions, the surface of the thalamus, cerebellum, and hippocampus and exerts 
sporadic activity 206, 207. Moreover, Mdm2 conditional mouse models demonstrated that loss 
of Mdm2 during CNS development exhibited massive p53 dependent apoptosis leading to 
degeneration of the neuroepithelium and the cortex 208. Similar to the human brain, the mouse 
brain develops from NSCs during embryogenesis. Some studies have identified the presence 
of p53 in neurogenic niches such as the SVZ 209. Neurosphere in vitro assays from p53 null 
mice demonstrated higher capability of self-renewal and less apoptosis 209, 210.  It has been 
shown that p53 inhibits the BMP-SMAD pathway assessing the differentiation potential of 
NSCs from p53 -/-  mice. BMP-SMAD inhibition suggests that loss of p53 increases proliferation 
and self-renewal of neurospheres and promotes neural differentiation 211. Of note, all studies 
performed so far have been done in mice hence the role of p53 during human neurogenesis 
remains unclear. 
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2 AIMS 
The general aims of this thesis were (i) to develop in vitro and in vivo models using patient-
derived IPS cells to mimic the early developmental malignancies Neuroblastoma (NB) and 
Medulloblastoma (MB). (ii) To study the role of p53 during human brain development. The 
aims are further divided into sub-ordinate aims: 
(i) 
I. To generate patient-derived iPS cells from two NB patients 
II. To establish a robust protocol for the generation of NCC from iPS cells 
III. To model ALK driven-NB using patient-derived iPS cells in vivo 
IV. To model SHH-MB using Gorlin patient-derived iPS cells 
(ii) 
V. To establish human in vitro models to study p53 during brain development 
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3 RESULTS AND DISCUSSION 
3.1 A MODEL FOR ALK-DRIVEN NB USING PATIENT-IPS CELLS (PAPER I, II, 
AND III) 
iPS cells and their derivatives mimic early stages of human development, which makes 
them an attractive model to study early onset diseases such as childhood cancers, which 
are thought to originate in stem or progenitor cells 139. Therefore, in paper I and paper II, 
the resources necessary to model childhood cancers were created 212, 213. In paper III we 
use the resource created to model NB development by orthotopically injecting patient-
derived NCC in the adrenal gland of immunocompetent mice.  
NB is an embryonic childhood cancer that, despite being rare, presents a high mortality rate 
in infants. The adrenal gland, derived during PNS development, is one of the most common 
locations for primary NB tumors. We established a patient-derived iPS cell model to study 
initiation and progression of NB. Gain-of-function mutations of ALK are a characteristic of NB 
35. ALK mutations can be both hereditary or somatically introduced. To further evaluate 
whether NCC from NB patients carrying a germline mutation in ALK are capable of mimicking 
human NB, we injected NCC obtained from patient-derived iPS cells into the right milieu, the 
adrenal gland. 
Generation of patient-derived iPS cells - Paper I 
The NB patients used in this study belong to the same family and carry a germline ALK 
R1275Q mutation (Figure 15). Skin biopsies were used to establish fibroblast cultures and 
subsequent generations of iPS cells. To establish patient-derived iPS cells, NB1, NB2, and 
NB3 patient fibroblast cultures were set up using enzymatic dissociation from skin biopsies 
as previously described 214. Unfortunately, due to technical issues during the isolation of 
fibroblasts, NB3 cells could not be successfully established. Primary patient fibroblast 
cultures, of NB1 and NB2, were not passaged more than 5 times previous of initiating 
reprogramming to avoid induction of senescence 215. Of note, patient fibroblasts were first 
seeded on inactivated human foreskin fibroblasts, and subsequently maintained in different 
cell culture conditions. SeV (OSKM) reprogramming was utilized, as it presents a non-
integrative and relatively efficient method compared to other non-integrative systems (Figure 
8). Importantly here, using a non-integrative method is essential to avoid risk of mutagenesis 
and implication of other variables during tumorigenesis, assessed in paper III.  
 
 
 
Figure 15. Family Pedigree. NB3 patient was not diagnosed but 
carried ALK R1275Q mutation. NB2 and NB1 patients were 
diagnosed with NB and carried same germline mutation in ALK.  
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After fibroblast were transduced colonies were manually picked around 4 weeks later (Figure 
16). Several clones were established from each cell line and frozen down for further analysis.  
Figure 16. Example of reprogramming flow. NB fibroblast reprogramming in a feeder-dependent 
system using Sev. 
In Paper I, we picked one clone of each cell line resembling ES cells morphology, including 
sharp edges, big nuclei and little differentiation. As previously mentioned, SeV can stay within 
the cell for several passages. To make sure the iPS cells were endogenously expressing 
pluripotency factors we passaged them for at least 12 times and confirmed loss of SeV using 
PCR before proceeding with the validation. 
First, iPS cells derived on a feeder-dependent system were validated for pluripotent gene 
expression using cytoimmunochemistry and the pluriTest bioinformatics tool. Importantly, 
improvement of cell culture conditions were shown to stabilize pluripotency, increase 
efficiency of reprogramming, standardize culture of iPS cells and decrease the chances of 
chromosomal abnormalities 120. Both are relevant features to establish long-term cell culture 
of iPS cells for any potential purpose. Since cell culture conditions are important for the 
maintenance of pluripotent stem cells we decided to optimize our culture conditions based 
on publications using a defined and xeno-free system of medium in combination with 
recombinant human laminins 216. In 2000 Amit et al, identified that bFGF supplementation was 
required when FBS was removed from the medium composition 217. Examining this, already 
in 2006, a defined medium termed TeSR1 was developed for usage in feeder-free conditions. 
This medium developed by Ludwig et al 123 solely included recombinant sources of human 
purified proteins; for example high concentrations of FGF-2, lithium chloride, γ-aminobutyric 
acid (GABA), TGF-β, and pipeolic acid. More recently, TeSR1 was chemically reduced by 
diminishing all the components to a number of eight (E8), lacking for instance serum albumin 
and β-mercaptoethanol thereby reducing a source of variability 218. Because of all the benefits 
that defined medium combined with feeder-free conditions supported, we decided to 
transition our iPS cells to defined E8 medium. Concerning the extracellular matrix, matrigel is 
the most common and widely used matrix to culture iPS cells. However, due to its animal 
origin and batch-to-batch variability it did not fit the purpose of standardization of cell culture 
conditions that we aimed for. Laminins are heterotrimeric proteins and components of the 
ECM containing an α, β, and γ chains that are found in five, four, and three different genetic 
variants respectively. LN-511 and LN-521 have been shown to be expressed in the human 
pre-implantational embryo and ES cells. First it was shown that LN-511 could maintain self-
renewal of human pluripotent stem cells for more than 20 passages 127, 219. Later on, long-term 
self-renewal of human iPS cells was supported by LN-521 as well 216. Therefore we decided 
to combine E8 medium with LN-521 in order to obtain defined and xeno-free conditions. After 
the transition to the new cell culture conditions, we evaluated the expression of pluripotency 
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markers on our iPS cells. Patient iPS cells expressed NANOG and OCT4 at mRNA and protein 
levels. Pluripotency markers such as SOX2, SSEA-4, and TRA-1-81 were assessed at protein 
level either by immunochemistry or flow cytometry. Furthermore, flow cytometry analysis 
indicated a homogenous cell population of undifferentiated cells which demonstrated the 
reliability of our conditions. Moreover, SeV backbone was detected in early passages of iPS 
cells whereas it was no longer present in later passages. This implied that expression of 
pluripotency markers was indeed endogenous and not promoted by the reprogramming 
factors. Previously, we mentioned that PluriTest is a bioinformatic tool that facilitates validation 
of iPS cells via interrogation of big data sets of somatic and pluripotent expression profiles. 
The generated iPS cells were scored for pluripotency and novelty which are parameters 
defined by the test. The pluripotency score is based on a pluripotency signature whereas the 
novelty score indicates how similar the samples of interest are compared to already 
established and characterized pluripotent stem cells. PluriTest was assessed before and 
after the change of culture conditions and was shown to not be affected when compared to 
a feeder-dependent system (data not shown, Kele et al, Manuscript).  NB1 and NB2 iPS cells 
were confirmed to be karyotypically normal and retained the ALK mutation. In vitro 
differentiation was assessed using EB formation, after 3 weeks mRNA expression of ecto-, 
endo-, and mesoderm markers were evaluated either by RT-PCR or qRT-PCR. We observed 
that markers of the three germ layers such as NCAM, RUNX1 and AFP were upregulated 
compared to iPS cells. This demonstrated the potential of the obtained cells to differentiate 
into all the three germ layers. In summary, in paper I we show the generation of fully 
characterized iPS cells from two different NB patients carrying a germline mutation in ALK. 
Human neural crest cells from pluripotent stem cells using robust, defined, xeno-free 
conditions - Paper II 
Next, we needed to establish a protocol to derive NCC from the patient-iPS cells. NCC have 
a great multi differentiation potential and its development occurs during gastrulation 
dependent on the BMP and WNT signaling pathways 220. Ethically, studying NCC biology in 
humans has been limited to just few observational studies in embryos 221. Therefore, most of 
our knowledge is based on studies of vertebrates such as zebrafish, xenopus and chicken. 
It has been established that the mesoderm produces antagonists during neural tube 
formation, that modulate BMP signaling and  help the specification of neural, neural crest, or 
epidermal lineages 222. It is clear that BMP activity is important for NCC differentiation but the 
mechanisms underlying this process are poorly understood. In vitro, BMP ligands are usually 
present in the media or produced by the cells that makes it overall difficult to dissect out other 
variables influencing induction 223. This, and different needs during temporal differentiation, 
are a few of the reasons why some protocols rely on and other protocols avoid usage of BMP 
inhibition 165, 166.  
In vivo, human NCCs were shown to express markers, like SOX10, PAX3, TFAP2a and p75 
neurotrophin receptor (NTR), that are also present in other vertebrates. The genetic network of 
NCC induction, differentiation, and specification is complex and transient 158. The induction 
of BMP, FGF, and WNT among pathways during development, triggers expression of specific 
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transcription factors that can be used as markers. Examples are; border specifier genes Pax3 
and Pax7, signaling molecules TFAP2a, SOX9, and SOX10 as neural crest specifiers that are 
relevant during migration and differentiation of NCC 221. As mentioned, some of these genes 
have been studied in other systems indicating their relevance during NCC development. For 
example, PAX3, SOX10, and TFAP2a mice mutants display NCC defects 224, 225, 226. In vivo 
human embryo studies demonstrated the presence of PAX3, SOX9, SOX10 in pre-migratory 
NCCs during the 4th gestational week. Moreover, additional rostral sections indicated the 
presence of TFAP2a and p75 NTR .  
In paper II we demonstrate that controlled intermediate levels of BMP promote NCC 
differentiation in a robust and efficient manner. The developed protocol is defined and xeno-
free method which provide robustness, less variability, and more reproducibility. To establish 
this, we modified a protocol based on SMAD dual inhibition and WNT activation (NCN2 
protocol). After 7 days, we sorted for p75 high (++) expressing cells which have previously 
been shown to be enriched for SOX10, PAX3, TFAP2a and concomitantly downregulation of 
the pluripotency marker OCT4. NCC-derivatives were generated to validate NCC identity. In 
order to do so, a SOX10-GFP reporter ES cell line was used. Based on GFP expression, 
SOX10 cells were sorted and differentiated into mesenchymal cells, osteocytes, 
chondrocytes, as well as peripheral and sensory neurons. Moreover, we found that NCC were 
highly migratory and expressed ETS-1, a cranial NCC marker. Altogether showing the 
multipotency and functionality of the generated NCC cells. However, the NCN2 protocol did 
not always produce NCC with similar efficiency or quality, suggesting that the protocol 
needed more optimization.  We observed that efficiency correlated with endogenous levels 
of BMP4. In case of too low BMP4 levels, BMP4 was added to the media resulting in 
increased efficiency of NCC generation. On the contrary, the addition of Noggin, a BMP 
inhibitor, led to a decrease in the efficiency of NCC generation. Thus, NCC differentiation 
requires precise levels of BMP4. To avoid fluctuations in BMP4 levels during NCC 
differentiation a “top-down inhibition” (TDi) system was developed, which involved saturating 
cultures with exogenous BMP4 while blocking endogenous BMP4 production using a BMP 
type 1 receptor inhibitor (DMH1) (Figure 17).  This resulted in controlled and stable levels of 
BMP4 throughout the differentiation protocol and permitted the cells to differentiate optimally 
to NCC and avoid induction of genes that are 
associated with non-neural ectoderm, meaning that the 
use of TDi reduces variability and increases efficiency 
of generation of NCC from human pluripotent stem 
cells.  
 
Figure 17. Top down-inhibition strategy. Hackland et al, 
Stem Cell Reports, 2017, with permission from the publisher. 
Modeling NB in vivo – Paper III 
In Paper I we demonstrated the generation of patient-derived iPS cells from two NB patients 
with ALK R1275Q mutation 212 and in Paper II we developed a robust protocol for generating 
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NCC, the cell type thought to be the origin of NB. In Paper III we applied the NCC 
differentiation protocol on the patient-derived iPS cells to study the contribution of the ALK 
R1275Q mutation on tumor development. First, we transduced the iPS cell lines with a 
luciferase reporter in order to monitor them in vivo. Subsequently, we differentiated iPS cells 
into NCC using the defined and xeno-free conditions established in Paper II.  We derived 
NCC from a fully validated control iPS cell line (Ctrl7) 227, which successfully differentiated 
into p75 high positive cells and exhibited the elevated NCC markers PAX3, SOX10 and 
TFAP2a. Minimal variability in gene expression profile was observed between three separate 
inductions demonstrating the robustness of the NCC protocol. Next we proceeded with 
assessing the NCC differentiation potential of the patient-derived iPS cells. Both NB-iPS cell 
lines were able to generate a p75 high cell population and NCC markers were observed at 
mRNA and protein levels. While we could not detect any differences in NCC induction 
efficiency or marker expression between control and patient derived NCC, we observed an 
upregulation of MYCN in patient NCC compared to control NCC, indicating a possible 
collaboration between ALK and MYCN in the patient cells. In vitro studies in patient NCC 
need to be further evaluated in order to identify possible differences of NCC and derivatives 
between patient and control NCC.  
In order to establish a NB model from patient-derived NCC, we sorted p75 high cells from 
control and patient cells. We proceeded to surgically inject NCC orthotopically into the 
adrenal gland of 6 to 8 weeks NOD/SCID/IL2Rg-/- (NSG) mice.  IVIS imaging was used in order 
to follow progression of growth in vivo. While mice injected with control cells did not show 
any symptoms for a period of almost a year, the luciferase signal increased in some of the 
patient-derived NCC after 24 weeks post-injections. After one year, the adrenal glands were 
harvested for immunohistochemistry analysis. H&E staining and different NB diagnostic 
markers such as PHOX2B, and NCAM, identified that in a cohort of 12 mice, one NB1-NCC 
injected mice developed ganglioneuroblastoma. Ganglioneuroblastoma is a more benign 
and differentiated form of NB (NB1NCC#3) 228. On the other hand, mice injected with NB2-
NCC, that presented a slower increase of the luciferase signal than NB1, developed an 
undifferentiated structure which was unable to identify utilizing available NB diagnostic 
markers (NB2NCC#12). Moreover, we observed calcifications and bone formation upon 
injections of patient-NCC (NB1NCC#9) indicating the potential of NCC differentiation into their 
derivatives in vivo. Indeed, the diversity of our results demonstrates that the mice cohort 
needs to be increased, in order to confirm low penetrance of ALK driven-NB. However, it 
would be interesting to analyze the ALK activation pathway during NCC derivation and 
differentiation, to understand when ALK is active during this process and whether 
tumorigenesis is originating due to this driver mutation.  
Overall, we present a new way of utilizing patient-derived iPS cells to model NB which has 
the potential to reveal ALK implications during NB initiation and progression. 
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3.2 MODELING SHH-MB USING IPS DERIVED NES CELLS (PAPER IV) 
Medulloblastoma (MB) is the most common childhood brain tumor and develops from a 
progenitor population in the developing cerebellum.   
Human neuroepithelial stem cells (NES) are neural stem cells residing in the neuroepithelium 
during brain development. NES cells have the ability to self-renew and also differentiate into 
RG or neurons taking an important role during neurogenesis. It is possible to capture NES 
cells from early embryos but they can be derived from iPS cells as well 154, 229. iPS derived-
NES cells show a gene expression profile closely resembling human embryonic hindbrain 
identity. Therefore, NES cells match the cerebellum position identity and thus present an ideal 
tool to model MB. In vitro, long-term NES cells are capable of self-renew for more than 100 
passages when cultured in FGF and EGF conditions and 90% differentiate into neurons while 
10% differentiate into glia upon removal of growth factors. Overall, the position identity and 
differentiation behavior demonstrate that NES cells are an important tool to model MB 229. 
Gorlin syndrome (also named Nevoid basal cell carcinoma syndrome) patients are prone to 
develop basal cell carcinoma, as well as MB, due to a germ line mutation in one allele of 
PTCH1 and resulting in aberrant activation of the SHH-pathway. In Paper IV we aimed to 
model SHH-subgroup MB. In order to model SHH-subgroup MB we used non-cancerous 
cells from two Gorlin syndrome patients carrying different PTCH1 germline mutations, which 
we refer to as G1 and G2 respectively. Both PTCH1 mutations lead to frameshifts resulting in 
PTCH1 protein truncation. Keratinocytes of these patients were reprogrammed into iPS cells 
and differentiated into NES cells. When grown in vitro, we found that Gorlin NES cells did not 
show differences compared to control NES unless grown in a 3D system or in hypoxic 
conditions. The lack of difference suggests that SHH pathway activity might be lost in cells 
grown in a monolayer 230. Next, Gorlin NES cells were transduced with a luciferase reporter 
and were orthotopically transplanted into the cerebellum of immunodeficient mice and 
followed in vivo using a bioluminescence in vivo imaging system (IVIS). Luciferase signals 
were detected in mice from 8 weeks post-injection with Gorlin patient cells, whereas no signal 
was detected up to 52 weeks post-injections with control cells. Upon harvasting and 
subsequent investigation of mice brains we observed tumors in the cerebellum. The tumors 
consisted of small, round, and blue cells and were either of desmoplastic or classic MB 
histology which resembles human SHH MB samples. The tumor cells could be isolated and 
cultured in vitro as neural stem cells (referred to as tNES from here) and generated secondary 
tumors with accelerated tumor growth when re-injected into mouse cerebellum. 
Tumor cell gene expression was analyzed by RNA sequencing (RNA seq), and using 
principal component analysis (PCA) was found to group with human MB tumors Furthermore, 
profiling using expression data from human MB samples revealed that the tumor cells, 
primary and secondary tNES, showed a gene expression profile resembling SHH-subtype of 
human MB, demonstrating that Gorlin patient NES cells form tumors in vivo that faithfully 
mimic human SHH-driven MB. 
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Gene set enrichment analysis generated from tNES RNA seq, revealed a progressive 
upregulation of inflammatory and EMT pathways in the tumor cells. Interestingly, we found 
upregulation of LGALS1 or Galectin-1 which has been correlated with metastasis and poor 
prognosis in many types of cancer. Especially in the SHH-subtype of MB, high LGALS1 
expression is correlated to worse overall survival. Thereafter, to investigate the importance of 
LGALS1 we used OTX008, a specific Galectin-1 inhibitor, we used OTX008, a specific 
Galectin-1 inhibitor. Treatment with OTX008 led to decreased proliferation of Gorlin but not 
control NES cells, suggesting LGALS1 as a new potential target to treat SHH-driven MB. 
To summarize, in paper IV, we demonstrate that NES cells generated from reprogrammed 
non-cancerous somatic cells carrying a PTCH1 germ line mutation give rise to MB when 
injected into immunocompetent mouse cerebellum. We created a novel human cell model of 
SHH MB using NES cells generated from Gorlin iPS cells, and studied their tumorigenic 
potential in vivo. We believe that our model will lead to the discovery of novel oncogenic 
mutations, which in turn help us to better understand MB initiation and progression. Thereby, 
this approach may prove beneficial for drug screening purposes. 
3.3 P53 IN HUMAN BRAIN DEVELOPMENT (PAPER V) 
TP53 is a tumor suppressor gene that is mutated or inactivated in 50% of all human cancers. 
Acting as the guardian of the genome, it regulates many processes in the cell including, 
genomic stability, cell cycle arrest, and differentiation. These functions are extensively 
studied in a cancer context and to some extend in mouse neural stem cells. In paper V, we 
use a 2D and 3D in vitro approach to assess the role of p53 during human neural 
development.  
3D cerebral organoids derived from iPS cells have been shown to closely mimic early brain 
development both transcriptionally and epigenetically 186, 231. To further investigate the role of 
p53 in neural stem cell function and differentiation, we used a 2D monolayer of human NES 
cells. We believe that the combination of both in vitro systems can aid understanding of 
specific functions of p53 during brain development. Figure 18 represents both the complexity 
and homogeneity of different systems. Whereas 2D in vitro systems such as NES cells are 
highly homogenous, 3D whole brain organoids resemble complexity of the human brain more 
closely. Current 2D models, although versatile and homogenous, quite often contain pure 
cell populations with solely one cell identity. Despite its limitations, the potential of this system 
is immense, especially considering a certain lineage specification (See example in paper IV). 
On the other hand, due to the formation of different types of cells and stem cell niches such 
as the VZ, SVZ, and neuronal layers 3D systems offer a higher complexity. However, 
spontaneous self-organization and heterogeneity usually result in increased variability. 
Nevertheless, 3D systems present a good tool to investigate pathogenesis underlying strong 
phenotypes as has been shown previously 168.  . 
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Figure 18. Homogeneity and Complexity of neural in vitro systems. Kelava et al, with permission from 
the publisher, Cell Stem Cell. 
In Paper V, we used two different iPS cell lines derived from healthy individuals 232 and three 
different lentiviral shRNAs, two shRNAs target different regions of TP53 and one is a control 
shRNA. We knocked down (KD) p53 and generated whole brain organoids. We observed 
that p53 KD organoids are able to form self-organizing structures, albeit with less efficiency 
in generating cortical tissue. For these reasons, we evaluated different stages of the 
developing cortex. Whereas SOX2 expression is a good indicator of the NSC layer in the 
brain 233 234, TBR2 and TBR1 positive cells suggest NSC differentiation towards post-mitotic 
projection neurons 235. Sequentially, TBR2 is expressed in intermediate progenitors and 
usually emerges after downregulation of PAX6. Whereas, TBR2 is downregulated in later 
stages of cortex development TBR1 expression is present. Therefore, to gain a general 
overview of cortex development, we analyzed SOX2 expression and quantified the key 
cortical developmental markers TBR2 and TBR1 in whole-brain organoids. We observed 
delocalization of the stem cell layer recognized by expression of SOX2. Quantification of 
TBR2 and TBR1 revealed a reduction of TBR1+ neurons generated in the p53 KD cortex. 
Since this indicates that either the stem cell function or differentiation potential of the NSC 
were impaired, we proceeded by knocking down p53 in a 2D in vitro system of NES cells. 
Upon loss of p53, NES cells still exhibit stem cell markers and classical rosette-like 
morphology. This suggests that loss of p53 did not affect self-renewal properties. 
Furthermore, analysis of the cell cycle revealed that cells accumulate in the G2/M phase. In 
combination with detectable amplification of centrosomes, it pinpoints p53’s role in 
maintaining cell cycle progression and centrosome regulation in human neural stem cells. To 
gain a deeper understanding of the functions that p53 plays in human NSC we analyzed the 
transcriptome of p53 KD NES cells and found that metabolic pathways such as oxidative 
phosphorylation were downregulated. Among the upregulated processes, we observed CNS 
neuron differentiation. Since the NES cells were still expressing NSC markers, but 
transcriptomic analysis indicated a priming towards differentiation, we differentiated the NES 
cells into early neurons by removing growth factors in the media. Functional analysis of these 
neurons revealed a more mature state after 15 days than control neurons, as indicated by an 
increase in calcium oscillations. Furthermore, after 30 days of differentiation, the p53 KD 
neurons gained oxidative phosphorylation as a main source of energy, indicative for maturing 
neurons and correlating with previous calcium data. 
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In conclusion, we demonstrate that p53 is required for the proper localization of neural stem 
cells in 3D organoids. In addition, by using a 2D NES cell system we unraveled the 
involvement of p53 in genome stability and energy metabolism of human neural stem cells. 
Whereas 3D brain organoids mimic the in vivo situation of neocortex development, including 
structural and cellular complexity, NES cells are a much more homogenous system with 
hindbrain identity. The 3D organoid system offers the investigation of p53’s role in brain 
development, starting from p53 downregulation in the iPS cell, before brain formation. At the 
NES cells stage we captured occurring processes during a specific timeframe and did not 
consider previous events before generation of NES cells. We believe that by using a 
combination of tools we can examine the role of p53 from different perspectives and in a 
continuous manner throughout brain development. Using p53 KD brain organoids we clearly 
observed abnormalities in the structural organization of the stem cell layer and lower 
efficiency of generated tubular regions, including significant downregulation of the cortical 
marker TBR1. However, possible functional experiments are more complicated to assess in 
this system. 30 days old brain organoids, which is the time when the neuroepithelium 
establishes, were examined. This time point has previously been shown to resemble closely 
the human brain development (Figure 13). Therefore, after studying organoids exhibiting 
delocalization of the stem cell layer upon loss of p53, we moved on to the NES cells system 
to further examine the role of p53 in a more simplistic manner. For example, the NES cells 
system allowed for the detection of several phenotypes which were intricate to uncover in the 
brain organoid system. Furthermore, investigating the number of centrosomes per cell and 
to functionally explore the differentiation potential of human NSC was only able in the NES 
cell system. 
We believe that these results aid to the understanding of p53 in human brain development 
and function in an otherwise mouse model and cancer research dominated field. 
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4    CONCLUSIONS AND FUTURE PERSPECTIVES 
Cancer is one of the most common leading causes of death worldwide. Even though 
childhood malignancies are rare, they still are the most frequent cause of death in children 
after infectious diseases. Current therapeutic options to treat children can have severe 
permanent side effects. Childhood cancers occur during early human development which 
implicates difficulties in treatment possibilities as well as limitations in finding the origin of the 
disease. The main aim of this thesis has been to establish new ways of modeling childhood 
malignancies to facilitate a future understanding of the onset of the disease as well as a new 
potential tool of anti-cancer drug identification. 
In order to do so, we took advantage of the immature state of iPS cells which have been 
derived from NB and MB patients. Next, we successfully derived different in vitro progenitors 
such as NCC and NES cells which belong to specific developmental lineages during PNS 
and CNS development. We wanted to investigate the effects of non-cancerous cells carrying 
germline mutations that predispose to cancer when injected into a permissive environment. 
After generating all the resources needed we used immunocompromised mice to inject the 
respective labeled progenitors into the right environment and monitored them in vivo. 
NES cells are a robust, well established in vitro system with hindbrain identity, representing 
a perfect tool to mimic MB. On the other hand, NCC are much more transient and 
unfortunately, we were not able to capture them in vitro for an extended time. Whereas the 
data shown for the NB model still is preliminary, the MB model allowed us to developmentally 
mimic the initiation of human MB, establish in vitro NES cultures from MB tumors from mouse 
cerebellum, and use the cells for the identification of potential clinical targets.  
This work presents the possibility of studying many inherited mutations in cancer or 
associated syndromes. The iPS cell technology opens new possibilities and approaches to 
study complex human diseases. It proves especially advantageous for those with early onset. 
We believe that understanding the initiation and development of cancer from the first hit will 
aid identifying potential new clinical targets, improve the current treatments, allow a better 
and more accurate prognosis, and to possibly find new biomarkers. 
On the other hand, brain organoids derived from iPS cells have been a big revolutionary tool 
to study the developing human brain. The work presented here merges different human in 
vitro systems to understand the overall function of p53 during human brain development. Of 
note, to our knowledge all previous reported studies have been performed in mice. p53 is an 
important player during cancer development, however mutations in p53 mostly occur in adult 
cancer and during later stages of the disease. Cancer is a heterogeneous disease which 
does not solely depend on cancer cells, but surrounding tissue and associated 
microenvironment are key components for the initiation, progression, and spread of the 
disease. More recently, tumor organoids have been generated from many primary cancer 
tissues and have been shown to be useful in identifying potential therapeutic approaches 236. 
Moreover, an organoid biobank from patient-derived healthy and tumor tissue samples has 
been established which brings us closer to personalized cancer treatment 237. These are only 
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a few examples that indicate the big potential of the organoid field in cancer research. We 
believe that iPS cells derived organoids could be utilized not only to understand development 
but also to understand the initiation of many cancers using the strategy that we present in 
this thesis. 
Summary 
(i) To develop in vitro and in vivo models using patient-derived iPS cells to mimic 
early developmental malignancies; Neuroblastoma (NB) and Medulloblastoma 
(MB). 
Paper I 
• We successfully establish and characterized iPS cells from two NB patients with 
familial ALKR1275Q mutation.  
Paper II 
• We generated a fully defined and xeno-free protocol for generation of human NCC 
from pluripotent stem cells. 
• We could identify endougenous BMP production as a source of variability for NCC 
differentiation in vitro, and by controlling the level of BMP4 during NCC differentiation 
we could increase the reproducibility of our NCC protocol. 
Paper III 
• We showed that NB patient-derived iPS cells are able to differentiate into NCC. 
• Orthotopically injected NB-patient NNC are able to survive in vivo, thus making it a 
potential new model to study the contribution of ALK mutation in NB development. 
Paper IV 
• We faithfully model human SHH-MB using Gorlin patient derived-iPS cells. 
• We showed that tNES are a potential model to use for identification of potential novel 
targets for MB. 
 
(ii) To study the role of p53 during human brain development. 
Paper V 
• We demonstrate that p53 is required for neural stem cell positioning in whole brain 
organoids. 
• We show that loss of p53 leads to genomic instability and changes in metabolic 
energy requirements in human neural stem cells 
• Upon p53 lost we show that NES cells are capable to differentiate into neurons 
reaching maturity faster than control NES cells.  
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place, nights over your cabin, saunas, wine, glöggs, laughs and conversations…I admire 
your patience, understanding and wisdom. You are such a strong and admirable woman!. 
To Kelly, the sweetest, kindest and sharpest person ever. I don’t know how to thank you for 
always listening and giving me the best advice. Thank you for your immense patience and 
tranquillity. Thank you for the past years in the lab, allowing me to learn and develop. Thank 
you for your truly friendship and for literally saving Robin and I in many occasions. You are 
so so good!!! And I have no wonder how brilliant your future will be. Thank you also to 
Mastoureh, your love and warmth has no limits. I really need to thank you for every time that 
you were there to cheer me up with your words. I will always appreciate how much you care 
and last but not least, how funny you are!! I wish you the best to you and your family J. 
Mohsen thank you for all the fun and priceless long island ice teas, mojitos, beers, wines and 
vermuts!! Thank you for caring and taking care of everyone. Thank you Salma, for always 
taking care so much of cell culture and being so sharing. Thank you Malin for helping in 
everything your time allows. Good luck with everything!. Elias, Matti, you are next in the 
queue, good luck!. Thank you Philipp for your amazing aura and hang outs!.Rebequita, 
disfruta mil! 
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A big thanks to Sonia Lain’s group which I spent a year before starting my Master’s degree 
at KI but a life changing experience. Muchas gracias Sonia to give me the opportunity to do 
my exchange in your lab, you literally open the doors for me to develop as a scientist and 
follow my gut feeling. Anna, I will never forget you, you were my very good friend. You always 
supported me and took care of me in the lab. Your lost was very painful but you have been 
always with me. I know I made a promise to you that I would keep strong during my PhD. 
Here I am today, it is almost done and I feel you have been always close to me for the entire 
journey  J. Gracias Inge por todo lo enseñado. Tú me entrenaste para trabajar duro y ser 
consistente. Tu pasión y coraje siempre me han admirado, muchísimas gracias por 
formarme!. Marcus, thank you so much for your comprehension, funny stories and 
especially, teaching me bad words XD. Thank you for helping me with all my questions before 
and during my PhD!. You will do amazingly good during your Postdoc!. Thank you Gergana 
for helping me so much with the migration assay experiments, without you that experiment 
would have never happened. I appreciate a lot your efforts and willingness to help me. Thank 
you! And Andrés por ser la alegría de la huerta! Muchísima suerte con tu futuro (quien sabe 
quizás mañana estás de vuelta!). Thank you Marijke for always teaching me in the lab when 
was needed and for your guidance during the past years. 
A big thanks to all the rest of MTCers, because you guys rock! You made these years full of 
laughs and extremely fun times!. Amandaaaa, separated by one simple floor for so long…it 
took us a while to get know each other ^^, you are my other half and you know in which skill 
we both excel, I don’t have to mention it!. Thank you because I have always a blast with you, 
with or without the tequila! XD <3. Thanks Jonathan for all the support and knowledge, and 
beers (that last one is also important). You are such an inspiration! Keep it always so cool! 
Joanna and Miland, you will do amazing in the US and I hope to see you guys really really 
soon! Thanks for all the fun times in the MTC pubs. Jacob, I miss you over here! It was such 
a great pleasure to share those 2 years at MTC, thanks for the good times and friendship. 
Sorry I got so sick in Australia :D. I will pay that one back!. Wisam was nice to share same 
floor and share small talks to realise some of our pressure. Thank you Marc for the super fun 
times before you left to US, it is great to have you back!. Good luck!. Thank you Birgitta, you 
literally saved me with your live sorting FACS skills when the biggest experiment I ever run 
was on going and almost about to fail!. I owe you a year experiment! Thank you for all your 
teaching and your love for these machines, I definitely inherited it!. Thank you Kenth for 
taking care of my little “mousies”. They meant a lot and you always made sure everything 
was in place!. Adam, I know you weren’t MTC but for me like you were, since anyhow the 
animal house has been always our meeting point. Thank you so much for all the support, 
massive help with the IVIS (you thought me everything I know) and your trust. You are simply 
a star! I am so happy for your new position!. Thank you Torun for being so great in the animal 
house, working with you made totally a difference. Thank you Per for always fixing my laptop 
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as soon as you could. You know by now much of a disaster I am. Thanks to Åsa and Gesan, 
for all your support and absolute dedication for PhD students wellness and success. 
Thanks to all collaborators that made this work happen J. A big thank you to Peter 
Andrew’s lab. Thank you Peter for giving me the opportunity to join your lab for a while. It 
was an amazing personal and professional experience and an absolute key contributor for 
the success of our work. Thank you so much Christian for fixing my stay in the lab and taking 
care of me during that time. And a massive thanks to Jim! Thanks for sharing your impressive 
knowledge and teach me how to generate NCC, it was such an honour to get to know 
someone that sharp and kind person like you. Good luck in the next step, you will rock it! 
Tom, bro! I can’t express how happy I am to have met you, you make me laugh sooo much 
(you know that). Thanks for all the help in the lab, and even after I left, for answering all of my 
annoying questions. Thank you so much for taking care and including me in your life during 
that time. Both of you, made that experience irreplaceable, really valuable and extremely 
positive! THANK YOU NCC TEAM! <3. Thanks to Daniel Bexell for believing in our project 
and kindly teach me one of the most challenging parts of my PhD; Orthotopic injections into 
the adrenal gland! Thanks a lot Daniel, I really enjoyed doing something so relevant. Thank 
you to Miklos, for taking your time examining all our sections and giving the best of your 
knowledge. 
 Thanks to my beloved students, for your impressive hard work that always made me feel 
so proud of you. Haizea, gracias por todo! Te echo de menos! Te veo pronto J. Jonne, 
thanks for your persistent, good and successful work, I am sorry not all of that is included in 
this thesis but don’t doubt that your work is a key factor for the progression of our work!. 
Astrid, you are such a big part of this. You are a hardworking and so intelligent angel, you 
literally helped me with everything and on top of that, I learnt so much from you. I am SO 
happy you came to us. You will do always amazing Astrid! “The team will never give up” <3. 
Thanks to all my dear KI friends, you know that without you I would not be the same and I 
would definitely have never achieved something like this…Thank you Elin! My beautiful 
Swedish girl <3. Thank you for all these years of true friendship, understanding and especially 
for all the love you have given me. I love you so much! The journey has been so much 
smoother having someone like you by myside. For more years to go! Manzanas and Lycka, 
are important concepts we have learnt through these years XD. Panda David, I am unsure 
how big of a fuss I can make here…but I just want to let you know that your kind and sweet 
soul, dedication and good spirit makes you unique. If I can be proud today that my thesis is 
at the minimum readable, is because of your massive efforts correcting, scratching and proof 
reading every single sentence on it. I can’t be more thankful for what you have done. Thanks 
for your extreme positive attitude and for being such a good friend, I am so lucky to have you 
around!. Thanks Alex for your valuable friendship and amazing times together! Thank you 
immensely for your constant caring. Your hard work will pay off and soon, you are also almost 
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done! I know you will do great!<3. Eliane, estoy tan agradecida de haber-te conocido. Eres 
totalmente la luz que me faltaba. Tan dulce y siempre tan atenta y ciudadora. Muchísimas 
gracias por cuidar de todos y de siempre estar ahí! Te aprecio un montón. Michael, thank 
you deeply for all the conversation and advice you have given to me, I really appreciate it! 
Keep putting my feet on the ground!. Thanks Mat for all the fun times but especially thanks 
for running 30 freaking Km together!. I would have not done it without you! I wish you the best 
luck in your new position, you will do GREAT!. Daniëlle, it was such pleasure to include 
another dutchie in my life! Thank you for the fun times and sharing experiences, hopefully 
more to come!. Konstantinos and Agnes, we need to go back to the training together! and 
then we will see results XD! so maybe also thanks to Mark for the hard core crosstraining 
classes, it helped me surviving this journey!. Konsta, it is unbelievable we know each other 
since the masters….time just flies. I wish you the best luck in your PhD and I will be there 
when it is your turn! Agnes, you are so sweet! And you are really the next! You can do this!! 
And with Vilma, you guys make the week much easier after meeting every Wednesday! 
Bagpippers it is! J. Thanks Vilma for all your interest and sharing knowledge. Thank you, 
Jens, for your positive mood, always ready for a blast! It was amazing to share the experience 
in Cold Spring Harbor course, NYC and Barcelona multiple times!. Diana, me alegro mucho 
de haber-te conocido, gracias por encontrar tiempo en Madrid y por todas las 
conversaciones que siempre he disfrutado mucho. Muchísima suerte, estoy segura que todo 
irá bien!. Gracias Sandra por ser tan rechill, gracias por estar ahí en todos los pubs aunque 
tuvieras que viajar desde Mordor!. Thank you Mathew for all the fun times since your day 0 
at KI!. I wish you the best during your postdoc! But let’s celebrate 30s first ;). Christina thanks 
for the fun time! 
Thanks to all of you KICC people! Especially Giuseppe, Carmen, Theresa and Milos. It has 
been a successful half a year thanks to you guys to make all of this happen! Thank you for 
your organization skills and for being so much fun in all the pubs and parties we have 
organized. Thanks to all organizers of the Winter Conference 2019 for your hard work to 
make it happen! Congrats!.Thanks to the Roslagshallen Squash club for all these years of 
fun and treating me so well. 
Thank you to my precious friends from the Master program! Thank you Axel for being such 
a good friend, for saving me of living on the street, for always including me in all your big 
plans like NYE and the best midsommar experiences I ever had! Thank you so much! You 
are next!. Thank you Sofie for your hospitality, kindness, and the best girl nights out ever! 
Hopefully for more of those to come!. Thanks William for all the crazy and amazing times 
during the masters and PhD, it has been such a pleasure to enjoy all of this with you guys! 
Álvarito, que sepas que siempre te admirado muchísimo! Eres una preciosidad de persona, 
trabajadora, encantadora e increíblemente inteligente. Te debo los mejores momentos 
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durante el máster y todas las conversaciones durante los momentos más duros durante este 
doctorado. Te quiero!  
Thank you Wale for all the support and taking care of me for the past years! You are such a 
good friend, I appreciate immensely your efforts trying to understand what is this science 
related problems about. Thanks Joel for your big support throughout the years. For always 
listening and understanding. Your critical mind has always been extremely helpful, thanks for 
all the advice!. You are almost done too!  
Marina Mandarina, que puedo decir? Indudablemente, conocernos ha sido una de las 
mejores cosas que me ha pasado en Suecia. Esos dos años viviendo juntas fueron una de 
mis mejores experiencias de mi vida y definitivamente, no hubiera sobrevivido sin ti. Aún así, 
todavía me debes un bulle en nuestro muelle J. Sabes que te quiero igual que a una 
hermana y que soy muy feliz de tenerte, pero más lejos de lo que querría :D. Gracias por tu 
apoyo incondicional durante todo este tiempo y por siempre estar ahí sin importar ninguna 
distancia. Te quiero mucho! 
Gracies a tots els amics de casa. Mariona, Maria i Amat són taaaaaants anys (25?). Es 
increïble! El temps no passa ni passarà per nosaltres. Mil gràcies per tot el suport durant 
aquests anys. Sé que no és fàcil mantenir relacions a distància i sincerament, vosaltres mai 
m’heu fallat. Us aprecio i us estimo moltíssim. Berni, que puedo decir! Eres el mejor joer! 
Gracias por estar ahí siempre, por nunca olvidarte de mi en la distancia, por visitarme el que 
más y por la de risas, aventuras y momentos de felicidad juntos! ¡GRACIAS por la mejor tapa 
del mundo! 
Gracies als trapeTlles de la uni! Boni i Dani merci per ser com els meus germans. Per el 
bon rollo que es veure-us com si el temps mai passés, per tots els momentazos que hem 
tingut junts. Merci per perdurar a la distància, us desitjo el millor!. Martí estic segura que si 
no fos per totes les hores que vam passar junts estudiant o comentant, mai hagués arribat 
on estic avui. Merci per tots els grans moments! 
A big thanks to the best Erasmus friends that are all spread around the world; Almu, sin 
duda una de las mejores experiencias de mi vida fue lo que vivimos juntas durante ese año. 
Nunca lo olvidaré y aún sonrío en pensar la de tonterías que pasaron. Gracias por todos 
estos años de soporte y por esta amistad que nunca se ve afectada por ninguna distancia. 
Auro and Paul, such beautiful love story right there! I am so glad to have been witness of 
that beginning. Thank you so much for your hospitality, it has been amazing to have you over 
and visit and experience your life in Ghent as well. I wish you could be there for the defence 
but we will arrange something instead! Auro, ya queda menos! Lo lograrás!. Karsten thanks 
for the eternal support and your big calmness. My favourite Australian, Nat. It was AMAZING 
to see you again after so long. I am so sorry that I got so sick XD. I hope you forgive me for 
that. I won’t forget your hospitality and generosity. I wish you the best for your future and I 
see you next in Europe!. Jeff, I cannot express with words your generosity, you made my trip 
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to Singapore and absolute amazing experience, I loved it incredibly much and I believe you 
made it like this. Thank you so much for everything and I hope next time we see each other 
is not in 6 years from now. Calum, I know there would be really few things that would impede 
you to be here to celebrate, but maybe being thousands km away and have an extremely 
difficult job like yours is excuse enough ;). You know how much I appreciate our friendship, 
how much you have helped me going through all the tough moments in the distance. Thank 
you for always caring and being there “online” when I most needed someone. Thanks for all 
the visits in Sheffield and Stockholm! Maybe next is Scotland then. Please, take care of 
yourself! 
Thanks to STEMCELL people!! Thank you Andrew or wait…thanks STEMCELL for randomly 
choosing me for a travel grant...XD. Ok Joking, thanks Andrew for being such an authentic 
inspiration. We met at the very last stretch of my PhD, but you have helped me keeping 
motivated until the very end!. Definitely crucial. Thank you so much for all the advice and 
enthusiasm!. Thank you Julia, for being such an inspiration; your energy, drive and hard work 
makes me feel so positive. THANK YOU for giving me the opportunity to be part of such an 
amazing team like yours!. I will do my best! I promise!. Éamon Ha! We will rock this! Thank 
you for being so genuinely nice and extremely helpful! I couldn’t ask for a better team leader!. 
A mi querida familia Marín Navarro, el más merecido de todos los gracias desde el fondo 
de mi corazón. A mi padres, Asun y Vicente, y a mi hermano Albert. Gracias por el apoyo 
sin fin, por inculcarme los valores más importantes de la vida, el trabajo duro, la buena moral 
y ética, la generosidad y el amor. Gracias por dejarme volar hacia lo más alto, por siempre 
apoyarme en las decisiones más críticas. Sin duda alguna, sin vosotros nunca hubiera 
llegado donde estoy. Gracias por todos vuestros esfuerzos, os quiero. Otro gracias para 
Albert por la foto que has creado para que la portada de esta tesis sea lo mejor de lo mejor! 
<3. Gracias a Roser, por ser la mejor cuñada del mundo!! Gracias por todas las increíbles 
comidas, cenas, fiestas, risas y mucho mucho amor durante los últimos años. Gracias a 
todos mis abuelos, Encarna, Carmen, Juan y Vicente, los que están y ya no están por 
formar parte de mi vida, por siempre preocuparse tanto en lo que hago tan tan tan lejos y 
donde hace tanto tanto frio!. A mi tía padrina, Carmen, por demostrar todo tu apoyo 
incondicional durante tantos años. Por enseñarme a pintar y dibujar y disfrutar de ello desde 
pequeñita. Gracias a mis tías, Encarnita y Toñi, por siempre estar ahí, cuidarme y siempre 
demostrar interés en lo que hago. Y por último gracias a todas mis primas, Carol, Laura, 
Nohemí y Raquel. Os deseo lo mejor en vuestras vida y a vuestras familias! 
From the bottom of my heart, thanks to all my “mousies” that have made possible all the 
work in this thesis, they made this work so valuable and fruitful. Thank you.
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